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ABSTRACT 
Barbituric and thiobarbituric acid derivatives have become progressively attractive to medicinal chemists due to their 
wide range of biological activities. Herein, different series of 1,3,5-trisubstituted barbiturates and thiobarbiturates 
were prepared in moderate to excellent yields and their activity as xanthine oxidase inhibitors, antioxidants, 
antibacterial agents and as anti-proliferative compounds was evaluated in vitro. Interesting bioactive barbiturates 
were found namely, 1,3-dimethyl-5-[1-(2-phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6c) and 
1,3-dimethyl-5-[1-[2-(4-nitrophenyl)hydrazinyl]ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6e), which showed 
concomitant xanthine oxidase inhibitory effect (IC50 values of 24.3 and 27.9 µM, respectively), and 2,2-diphenyl-1-
picrylhydrazyl (DPPH) radical scavenging activity (IC50 values of 18.8 and 23.8 µM, respectively). In addition, 5-[1-
(2-phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6d) also revealed DPPH radical scavenger 
effect, with an IC50 value of 20.4 µM. Moreover, relevant cytotoxicity against MCF-7 cells (IC50 = 13.3 µM) was 
observed with 5-[[(2-chloro-4-nitrophenyl)amino]methylene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7d). 
Finally, different 5-hydrazinylethylidenepyrimidines revealed antibacterial activity against Acinetobacter baumannii 
(MIC values between 12.5 to 25.0 µM) which paves the way for developing new treatments for infections caused by 
this Gram-negative coccobacillus bacterium, known to be an opportunistic pathogen in humans with high relevance 
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in multidrug-resistant nosocomial infections. The most promising bioactive barbiturates were studied in silico with 
emphasis on compliance with the Lipinski’s rule of five as well as several pharmacokinetics and toxicity parameters. 
 





Barbituric acid (BA) is a relevant pyrimidine derivative that was synthesized for the first time in 1864 by 
cyclization of urea and malonic acid [1]. Until the commercialization of benzodiazepines in the 1960s, 
barbiturates were almost the only group of drugs used as sedative-hypnotics [2, 3]. More recently, this class of 
compounds has become increasingly attractive to medicinal chemists due to the discovery that they bear a 
wide range of biological activities. More specifically, several of these compounds are enzyme inhibitors 
[collagenase-3, matrix metalloproteinases (MMPs) [4], xanthine oxidase (XO) [5] and methionine 
aminopeptidase-1] as well as antibacterial, anticancer, antiangiogenic, immunomodulatory, antifungal and 
antioxidant agents [6-9]. These activities are associated to several structural changes at positions N1, N3, C2 
and C5, the latter being the most studied position. Within these structural modifications, various cyclization 
reactions at C5 and C6 of BA, thiobarbituric acid (TBA) and their derivatives (BADs and TBADs, 
respectively) [10-19] as well as at C5 with spiro formation [20-24] have been described. Interestingly, some of 
these transformations involve a multicomponent reaction (MCR) [11, 14, 16]. However, in most cases, the 
cyclization path is preceded by the formation of substituted methyl [10, 18], arylidene [12, 15, 19-24], or 
methylene [13, 17, 19] derivatives at C5 as key isolated or potential precursors of these modified pyrimidines. 
Among the most important C5 functionalized BAs and TBAs are the 5-benzylidene or 5-methylene 
derivatives, usually produced usually by their reaction with benzaldehydes or triethyl orthoformate, 
respectively. Out of these, a large variety of 5-arylidene BADs and TBADs have been biologically evaluated 
and several compounds of this class was found to possess XO inhibitory effect [5] and antimicrobial activity 
against a number of Gram-positive and Gram-negative bacteria, as well as against fungal strains [25]. 
Methylene BADs and TBADs are most often used as intermediates for the synthesis of other derivatives [26, 
27]. Within these, hydrazone BADs have the ability to inhibit fungal growth in the μM range [28]. In addition, 
through the introduction of urea, thiourea, guanidine, hydrazine or hydroxylamino groups to BADs and 
TBADs, new bioactive compounds can be obtained [13, 17, 29]. 
XO is an important and versatile molybdo-flavoprotein responsible for the oxidation of purine substrates, 
catalyzing the conversion of hypoxanthine into xanthine and xanthine into uric acid, with subsequent 
reduction of oxygen, forming reactive oxygen species (ROS) which include the superoxide anion radical. An 
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increase in this enzyme’s activity, as well as in its metabolites levels (uric acid and ROS), are associated with 
many pathological conditions, including gout and oxidative damage of tissues [30-32]. Therefore, the 
discovery of new XO inhibitors, preferably with antioxidant capacity, is an important goal in medicinal 
chemistry [33]. 
Infections caused by microorganisms, especially those involving multidrug-resistant strains, place public 
health at serious risk. Acinetobacter baumannii is a bacterial species increasingly associated with nosocomial 
infections. Risk factors for an infection with this bacterium include prolonged hospitalization and recent 
surgical procedures. In this context, the identification of new antibacterial agents against A. baumannii, with 
new mechanisms of action, is an object of major efforts by the scientific community [34]. 
Taken together, the basic BA and TBA scaffolds may play a critical role in both XO inhibitory and 
promoting antibacterial effects. Therefore, in search for new active BADs and TBADs with these activities, 
herein we describe the synthesis and in vitro biological evaluation of 35 (16 new) 1,3,5-trisubstituted 
barbiturates and thiobarbiturates where position 5 was conveniently substituted with methylene, benzylidene 
and methyl derivatives. All BADs and TBADs were evaluated as XO inhibitors and their antioxidant activity 
was determined using the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging method. In addition, their 
antibacterial activity against several Gram-positive and Gram-negative strains and cytotoxicity towards 
normal human dermal fibroblasts (NHDF) and a mammalian cancer cell line (MCF-7) were assessed. 
Structure-activity relationships were also discussed and relevant pharmacokinetic and toxicity properties were 
calculated in silico to evaluate their potential interest for in vivo applications and/or in the development of 
compounds with improved pharmacological properties. 
 
2. Results and discussion 
2.1. Chemistry 
Thirty-five BADs and TBADs were synthesized as shown in Scheme 1, in moderate to excellent yields, i.e. 
41-97% (Experimental section and Table S1). The majority of 5-substituted BAD and TBAD families 
described herein are known precursors of fused heterocycles reported in the literature [10, 12, 13, 15, 17-24]. 
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From this set of compounds and to the best of our knowledge, two 5-phenylcyanomethylpyrimidines (4a-b), 
one 5-hydrazinylethylidenepyrimidine (6a), seven 5-phenylaminomethylenepyrimidines (7a-g) and six 1-
(pyrimidine-5-ylidene)ureas and thioureas (8a-c, e-g) are described for the first time. All starting materials 
were commercially obtained, except 1,3-diphenylthiobarbituric acid (1a) which was synthesized from 
phenylisothiocyanate, aniline, malonic acid and acetyl chloride, in two steps [35, 36]. Almost all prepared 5-
substituted BADs and TBADs were easily isolated in a high degree of purity by simple filtration, as confirmed 















A full spectroscopic characterization of all 5-substituted BADs and TBADs 2-8 was made, including 1H- 
and 13C-NMR shift assignments, which were established whenever possible with the aid of distortionless 
enhancement by polarization transfer (DEPT), heteronuclear multiple quantum coherence (HMQC) and 
heteronuclear multiple bond correlation (HMBC) experiments. The most representative 1H- and 13C-NMR 
chemical shifts of 5-substituted BADs and TBADs 2-8 are presented in Tables S2 and S3, corresponding to 
the structural moiety depicted in bold, in Scheme 1. 
5-Benzylidenepyrimidines 2a-e were synthesised by a Knoevenagel condensation reaction in excellent 
yields (90-97%), based on the method reported by Deb et al. [37] in which the reaction temperature was 
changed from 70 C to reflux. Then, the C-5 double bond of 5-benzylidenepyrimidine 2e was reduced at room 
temperature by NaBH4 in ethanol according to the method described by Yan et al. [38] to give compound 3, in 
41% yield. The change of the yellow arylidene color to white, due to a conjugation extension reduction, 
together with the absence of the 1H-NMR singlet at 8.25 ppm (2e unsaturated methine CH) and the 
observation of a triplet and doublet signals corresponding to the methine and methylene in adjacent carbons at 
3.82 and 3.19 ppm, respectively, observed in the 1H-NMR spectra of 3, are the most important evidences of a 
successful reduction reaction. Additionally, the cyanomethyl derivatives 4a-b were obtained, in 67-77% yield, 
from the respective 5-(4-bromobenzylidene)pyrimidines followed by the addition of sodium cyanide [39]. 
Once again the reduction was evidenced by the change in color of the solid to white and by observation of 
deshielded methylene CH 1H-NMR singlet signals at 5.24-5.35 ppm for compounds 4a-b. 
The 5-acetylpyrimidines 5a-c were synthetized using the process described by Jursic et al. [40] in good to 
very good yields (45-83%). Then, their hydrazine derivatives 6a-g were easily prepared after reaction with 
hydrazine and different phenylhydrazines, in refluxing methanol, using the method described by the same 
authors [40], also in good to very good yields (50-92%). 
The 5-phenylaminomethylenepyrimidines 7a-j and 1-(pyrimidin-5-ylidene)ureas/thioureas 8a-g were 
obtained in moderate to very good yields (52-98%) by reaction of triethyl orthoformate with urea or thiourea 
and different anilines, respectively, in refluxing butan-1-ol, by a MCR based on the method described by Rauf 
et al. [27]. In this procedure, the solvent was exchanged from butan-2-ol to butan-1-ol, which allowed the 
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increase of the reflux temperature, resulting in higher yields of products. As representative examples, the 
yields of 5-phenylaminomethylenepyrimidines 7h and 7j were changed from 82 and 72% to 97 and 84%, 
respectively, when the reaction temperature increased. 
Detailed 1H- and 13C-NMR analysis suggested that the enamine tautomer form A was present in all 
pyrimidine derivatives 6-8, in DMSO-d6. The imine form (hydrazone) B appears to be absent (Figure 1), 
contrary to what was reported for 5-hydrazinylethylidenepyrimidines [28]. Specifically, the NH 1H-NMR 
signal between 11.10 and 13.57 ppm correlated to the 5-C signal in HMBC experiments, which makes 
unequivocal evidence of the exclusive existence of tautomer A in DMSO-d6. 
 
Figure 1. Enamine A and imine B tautomeric forms. 
 
2.2. Xanthine oxidase inhibitory activity  
The evaluation of the XO inhibitory activity of BADs and TBADs 2-8 was made using a 
spectrophotometric method, under aerobic conditions, with xanthine as the substrate, and following uric acid 
formation by measuring the absorbance at 295 nm, as described in the literature [41, 42]. The commercial 
drug allopurinol was used as the positive control. The study started with a screening at 30 µM concentration 
(Table S4) and after this preliminary evaluation, concentration-response studies were performed for the BADs 
and TBADs which presented an inhibitory effect of 40% or higher, in order to determine their half maximal 
inhibitory concentration (IC50) values. 
In general, the majority of BADs and TBADs was able to inhibit XO activity (Table S4), with the most 
active compounds being the 5-benzylidenepyrimidines 2c and 2d and the 5-hydrazinylethylidenepyrimidines 
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6c and 6e (Figure 2), with an IC50 of 26.1, 31.5, 24.3 and 27.9 µM, respectively (Table 1). For the positive 
control (allopurinol) and under the assay conditions employed, an IC50 value of 3.17 µM was calculated, 
which is in agreement with the reported values [43]. Through the analysis of all these results, some important 
structural features for the XO inhibition could be inferred. Generally, BADs showed better XO inhibitory 
effect in comparison to their congeners TBADs, and bulkier substituents at C5 and smaller groups at N1 and 
N3 (Scheme 1) also seemed to favour this activity. Moreover, the 5-hydrazinylethylidenepyrimidine 6c, 
substituted with a methyl group at N1 and N3, clearly presented better activity than its hydrogenated analogue 
6d. Additionally, the presence of a 2,4-dinitro system (6f) seemed to reduce this activity when compared to 
the congeners 5-hydrazinylphenyl 6c and 4-nitrophenyl 6e (Figure 2). 
 
Figure 2. In vitro XO inhibitory activity of compounds 2c, 2d, 6c-f and allopurinol. Results are expressed 
as average values ± standard error of the mean (SEM). A p < 0.05 versus negative control in the 
statistical significance analysis (Student´s t-test) was observed for all compounds except for 6d. 
 
Table 1. In vitro IC50 values for XO inhibition and DPPH radical scavenging activity of compounds 2c, 






 DPPH (µM) a 
20 min 60 min 
2c 26.1 nd b nd b 
2d 31.5 nd b nd b 
6c 24.3 22.6 18.8 
6d nd b 23.9 20.4 
6e 27.9 23.9 23.8 
Allopurinol 3.2 nd b nd b 
Trolox nd b 33.8 35.9 
a IC50 values represent as mean of three determinations. 
b nd: not determined 
 
2.3. Antioxidant activity as DPPH radical scaveng er 
The DPPH radical scavenging activity of BADs and TBADs 2-8 was evaluated using a spectrophotometric 
method by measuring the absorbance of this radical at 517 nm, based on the available literature [41, 42] and 
using Trolox as the reference compound. A screening was first performed at the concentration of 30 µM, after 
20 and 60 minutes of incubation (Table S4). IC50 values were further determined for BADs and TBADs which 
presented a DPPH radical scavenging activity higher than 50% (Table 1). 
Most of the tested compounds presented no appreciable DPPH radical scavenging capacity (Table S4). 
However, 5-hydrazinylethylidenepyrimidines 6c-e were clear exceptions (Figure 3) and the determined IC50 
values were 22.6, 23.9 and 23.9 µM, respectively, at 20 minutes, and 18.8, 20.4 and 23.8 µM, at 60 minutes 
(Table 1). Particularly, under these experimental conditions, the radical scavenging ability of these 5-
hydrazinylethylidenepyrimidines was superior to the one observed with Trolox, whose calculated IC50 values 
(33.8 and 35.9 µM after 20 and 60 minutes, respectively) are in agreement with the literature [44]. Concerning 
the structural features relevant for this activity, the hydrazinyl derivatives globally presented higher DPPH 
radical scavenging capacity when compared with most of the other compounds. More specifically, the 
aromatic 5-hydrazinylethylidenepyrimidines 6c-e can be relevant starting points to develop improved 
antioxidant compounds acting as radical scavengers. In addition, it is interesting to note that the 5-
hydrazinylphenyl 6c-d and 5-hydrazinyl-(4-nitrophenyl) 6e derivatives had better activity than their 
hydrogenated 6a-b or 2,4-dinitrophenyl 6f-g counterparts. In this context, it is worth mentioning that the 
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antioxidant action of other different organic hydrazines has already been described [45-47]. Finally, the 1-
(pyrimidin-5-ylidene)ureas 8d and 8f exhibited a moderate radical scavenging activity (Figure 3). 
 
 
Figure 3. In vitro DPPH radical scavenging activity for 5-hydrazinylethylidenepyrimidines 6a-g, 1-
(pyrimidin-5-ylidene)ureas 8d, 8f and Trolox (positive control). Results are expressed as average values ± 
SEM. A p < 0.05 versus negative control in the statistical significance analysis (Student´s t-test) was observed 
for all compounds. 
 
Taken together, it is important to note the relevant XO inhibition and the high DPPH radical scavenging 
activity of the 5-hydrazinylethylidenepyrimidines 6c and 6e. As the new XO inhibitors should have a 
remarkable radical scavenging capacity, these results seem promising [43].  
 
2.4. Antibacterial  activi ty  
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The antibacterial potential of all synthesized BADs and TBADs 2-8 was studied in Bacillus cereus, 
Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Salmonella 
enterica subsp. enterica serovar Typhimurium and Acinetobacter baumannii strains, using tetracycline as the 
reference compound (Table S5).  
Regarding the antibacterial activity of the compounds under study, most of the assayed BADs and TBADs 
did not show activity against the tested Gram-positive and Gram-negative bacterial strains, with minimum 
inhibitory concentrations (MIC) higher than 200 µM. These results are in agreement with the previous reports 
referring to several 5-functionalized BADs and TBADs which were inactive against different strains of 
bacteria and fungi [28, 48-50]. However, pyrimidines 6c-d (MIC 25.0 µM) and 6e (MIC 12.5 µM) exhibited a 
relevant and selective antibacterial activity against A. baumannii. In fact, the presence of a p-nitrophenyl 
moiety bound to the hydrazine group of 5-hydrazinylethylidenepyrimidines (Scheme 1) seems to play an 
important role, since an increase in this antibacterial activity was observed in relation to the unsubstituted 
phenyl analogs 6c-d. In addition, the presence of more than one nitro group in the phenyl group (2,4-
dinitrophenyl derivatives 6f-g) decreased the activity of these 5-hydrazinylethylidenepyrimidines. Hence, a 
suitable aromatic substituent at R3 of these pyrimidines can favour this activity. Furthermore, it is important to 
note that compound 6d, with unsubstituted pyrimidinone nitrogens, had antibacterial activity against A. 
baumannii but was devoid of XO inhibitory effects.  
The emergence of infections and outbreaks associated with strains of A. baumannii resistant to antibiotics, 
or even extensively drug-resistant and pandrug-resistant, has highlighted the lack of available drugs to treat 
infections by this bacterium. In fact, carbapenem-resistant A. baumannii is marked as one of the critical 
pathogens in the World Health Organization priority list for research and development of new antibiotics [51]. 
Therefore, the activity of compounds 6c-e against A. baumannii makes them promising new starting points for 
the development of antibacterial agents against this high-profile pathogen. 
 
2.5. Cytotoxicity studies in human cells  
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Considering the relevant results observed in the XO inhibition, DPPH radical scavenging and antibacterial 
studies, the cytotoxicity of BADs and TBADs 2-8 was evaluated in normal human dermal fibroblasts 
(NHDF). Additionally, a mammalian breast cancer cell line (MCF-7) was included in this study to evaluate 
the anti-proliferative potential and selectivity of these compounds. The well-established 3-(4,5-
dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay [52] was used in which 
the soluble yellow MTT is converted into purple and insoluble formazan crystals by active mitochondrial 
lactate dehydrogenases of living cells [53]. Initially, both cell lines were exposed to BADs and TBADs 2-8 at 
the concentration of 30 µM, during a period of 72 h. Untreated cells were used as the negative control and 
cells treated with 5-fluorouracil (5-FU) as the positive control. 
The results (Table S4) showed that most of the compounds were not markedly cytotoxic for NHDF cells at 
30 µM. Additionally, the IC50 of 5-hydrazinylethylidenepyrimidine 6c was determined as a representative 
example of pyrimidines 6c-e, and a value of 82.0 µM was obtained. Considering the potential future use of 
this type of compounds in the treatment of A. baumannii infections, this can be an interesting result as it 
demonstrates a possible selectivity of these agents for bacterial versus normal human cells. 
On the other hand, a more marked reduction of MCF-7 cells proliferation was observed (Figure 4 and Table 
S4). The phenylaminomethylpyrimidines 7 seemed to have higher cytotoxicity than the other groups of 
compounds. Specifically, it is clear that the 5-hydrazinylethylidenepyrimidine 6d and the 5-
phenylaminomethylenepyrimidines 7d-e,g-h have a relevant anti-proliferative effect at 30 µM. In this last 
group, the presence of a chloro or a carboxyl group at position 2 of the aromatic ring (Scheme 1) seems to 
improve this activity when compared to the compound containing the nitro (7f) group in the same position. 
For the 5-phenylaminomethylenepyrimidine 7d, the most cytotoxic compound in MCF-7 cells at 30 µM, the 
IC50 value was 13.3 µM. Considering its selectivity for cancer cells versus NHDFs, this structure can be a 




Figure 4. In vitro cytotoxic effect of compounds 6c, 6d, 7a-j and 5-fluorouracil (5-FU) in normal human 
dermal fibroblasts (NHDF) and in mammalian breast cancer cells (MCF-7). Results are expressed as 
average values ± SEM. A p < 0.05 versus negative control in the statistical significance analysis 
(Student´s t-test) was observed for all compounds. 
 
2.6. In Silico studies 
 
Poor pharmacokinetics and/or unacceptable side effects are the main reasons why the majority of drugs 
evaluated in clinical trials do not reach the market [54]. Thus, computational approaches to predict the 
absorption, distribution, metabolism, excretion and toxicity (ADMET) may be a decisive tool to minimize 
these risks. The PkCSM online software (available from http://bleoberis.bioc.cam.ac.uk/pkcsm/prediction) is a 
recent freely accessible web platform that allows rapid evaluation of pharmacokinetic and toxicity properties 
and was herein used for the in silico evaluation of the drug-likeness, in terms of the Lipinski’s rule of five 
(Table S6), and to predict ADMET properties (Table S7) for the six most promising pyrimidines (2c,d, 6c-e 
and 7d) tested in vitro. 
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Four parameters are taken into consideration in the Lipinski’s rule of five, including an n-octanol-water 
partition coefficient (log P) no higher than 5, a molecular weight (MW) lower than 500 Da, no more than 10 
hydrogen bond acceptors (n-HBA) and no more than 5 hydrogen bond donors (n-HBD) [54]. Generally, an 
orally active drug has no more than one violation [55]. According to Table S6, all these pyrimidines are 
compatible with the parameters of the Lipinski’s rule of five, suggesting that these compounds have 
favourable properties to accomplish the drug-likeness criteria. 
The pkCSM online software was also used to predict pharmacokinetic and toxicity properties of 
pyrimidines 2c-d, 6c-e and 7d (Table S7). The pyrimidines 2c,d, 6c-e and 7d entirely fulfil the Lipinski’s rule 
of five and a good intestinal absorption was predicted. However, for compounds 2d and 6d-e a poor Caco-2 
permeability was estimated. In addition, despite the fact that pyrimidines 6e and 7d can be potential P-
glycoprotein substrates, it was predicted that all studied compounds should not be potential P-glycoprotein I/II 
inhibitors. Therefore, a low probability of pharmacokinetic interactions involving this protein is expected. A 
similar situation should occur in the case of the excretory protein organic cation transporter 2 (OCT2). In the 
distribution field, a generic tendency for a low probability for these compounds to access the central nervous 
system was estimated. Concerning metabolism, in which the cytochrome P450 isoforms have a key role, only 
the 5-phenylaminomethylenepyrimidine 7d was predicted to be a potential substrate of the important isoform 
CYP3A4. In general, it is expected that pyrimidines 2c,d, 6c-e and 7d should accomplish most of the 
pharmacokinetic and toxicity criteria studied, however, the estimated maximum tolerated dose in humans and 
potential genotoxicity (Ames toxicity) for several compounds (Table S7) appeared to be the potential major 
problems. In fact, a mutagenic potential for the nitroaromatic derivatives 2c-d, 6e and 7d is expected and 




A series of 1,3-trisubstituted barbiturates and thiobarbiturates substituted at the position 5 with benzylidene, 
benzyl, phenylcyanomethyl, acetyl, hydrazinylethylidene, phenylhydrazinylethylidene, 
phenylaminomethylene ylideneureas and the corresponding thioureas were synthesized, in moderate to 
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excellent yields. In addition, the activity of these compounds as xanthine oxidase inhibitors, antioxidants as 
well as antibacterial and anti-proliferative agents was also evaluated. Some of the synthesized barbiturates 
were found to have potential for health-related applications, namely 1,3-dimethyl-5-[1-(2-
phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6c) and 1,3-dimethyl-5-[1-[2-(4-
nitrophenyl)hydrazinyl]ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6e) which showed moderate inhibition 
of xanthine oxidase (IC50 values of 24.3 and 27.9 µM, respectively), and potent radical 2,2-diphenyl-1-
picrylhydrazyl scavenging activity (IC50 values of 18.8 and 23.8 µM. respectively). Aditionally, 5-[1-(2-
phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6d) was also highlighted as a relevant 
starting point for developing new radical scavengers. Interestingly, a selective antibacterial effect of 5-
hydrazinylethylidenepyrimidines 6c-e against Acinetobacter baumannii (12.5 to 25.0 µM MIC values) was 
observed with concomitant low cytotoxicity in normal human dermal fibroblasts. On the other hand, 
compound 5-[[(2-chloro-4-nitrophenyl)amino]methylene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7d) 
presented a relevant and selective anti-proliferative effect against MCF-7 cells (IC50 = 13.3 µM). It should be 
noted that the presence of a conjugated carbon-carbon double bond in some of the studied barbituric and 
thiobarbituric acid derivatives may affect the observed biological activity due to possibility of the compounds 
to act as Michael acceptors [56-58]. According to in silico studies, all selected pyrimidines 2c, 2d, 6c-e and 7d 
fulfil the Lipinski’s rule of five as well as most of the pharmacokinetic and toxicity criteria determined for the 
different ADMET parameters. Therefore, a novel compound class with members bearing xanthine oxidase 
inhibitory activity, antioxidant effects as well as anti-proliferative action and the ability to inhibit the growth 
of Acinetobacter baumannii was revealed. However, future studies should be performed to improve not only 
the potency and selectivity of this family of compounds but also its pharmacokinetics. 
 
4. Experimental section 
4.1. Chemistry 
All reagents were purchased from commercial suppliers and used without further purification. Reactions 
were monitored by thin-layer chromatography (TLC) on Merck-Nagel 60 G/UV254 (0.2 mm) plates which 
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were visualized by ultra-violet (UV) detection. Melting points were recorded on a Büchi B-540 melting point 
apparatus and are uncorrected. Infrared (IR) spectra were obtained with Thermo Fisher Scientific Nicolet 
iS10: smart iTR infrared spectrophotometer equipped with a diamond ATR crystal using OMNIC 8.2 
software. The sample spectra were collected at room temperature in the 4000-400 cm-1 range by averaging 32 
scans at a spectral resolution of 4 cm-1. 1H- (400.13 MHz) and 13C- (100.62 MHz) NMR spectra were 
performed on a Brüker Avance III 400 MHz spectrometer and were processed with the software MestReNova 
11.0.3 (trial). Chemical shifts were referenced to the residual solvent signal (DMSO-d6: δH = 2.50 and δC = 
39.52, or CDCl3: δH = 7.26 and δC = 77.16). The chemical shift (δ) values are given in parts per million (ppm), 
and the coupling constants (J) are given in Hertz (Hz). The multiplicity of the signals is reported as s (singlet), 
d (doublet), dd (doublet of doublets), dt (doublet of triplets), t (triplet), td (triplet of doublets) and m 
(multiplet). High resolution mass spectrometry (ESI-HRMS) was carried out on a Microanalysis QSTAR XL 
spectrometer by the microanalysis service (Salamanca, Spain). The 1H NMR and 13C NMR spectra of all 
compounds are presented on Supplementary Material. 
4.1.1. 1,3-Diphenylthiourea [35]. To a stirred solution of phenylisothiocyanate (1.00 mmol; 135 mg) in 
dichloromethane (0.5 mL) at room temperature, was added dropwise a solution of aniline (1.00 mmol; 93 mg) 
in dichloromethane (0.5 mL). The reaction was followed by TLC (dichloromethane) and completed in 3 
hours. The resulting suspension was filtered and washed with diethyl ether; Yield 95%; white crystals; mp 
142-144 °C (lit.[59] 140-142 °C); IR υmax (cm-1) 3202, 3053, 1598, 1526, 1491, 1449, 1342, 1313, 1288, 1242, 
1171, 1069, 1021, 1003, 933, 756, 694, 642, 629, 610; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 9.79 (s, 2H, 2 
× NH), 7.48 (d, J = 7.4 Hz, 4H, 2' and 6'-ArCH), 7.33 (t, J = 8.2 and 7.6 Hz, 4H ,3' and 5'-ArCH), 7.12 (t, J = 
7.4 Hz, 2H, 4'-ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 179.63 (2-CS), 139.46 (1’-ArC), 128.45 
(ArCH), 124.44 (4’-ArCH), 123.66 (ArCH). 
4.1.2. 1,3-Diphenylthiobarbituric acid (1a) [36]. A stirred solution of 1,3-diphenylthiourea (1.00 mmol; 
228 mg), malonic acid (1.30 mmol; 135 mg) and acetyl chloride (3.00 mmol; 235 mg; 214 µL) was heated at 
60 °C for 30 minutes. The solid product obtained was ground into finer powder, filtered, washed with water 
and recrystallized from acetic acid; Yield 95%; needle-like yellow crystals; mp 252-253 °C (lit [36] 258-259 
°C); IR υmax (cm-1) 3053, 2895, 1727, 1707, 1594, 1490, 1454, 1381, 1338, 1260, 1212, 1165, 1169, 1037, 
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1003, 927, 747, 696, 687, 667; 1H NMR (400 MHz, CDCl3) δ (ppm) 7.55 (m, 6H, ArCH), 7.21 (d, J = 7.3 Hz, 
4H, 6' and 2'-ArCH), 4.10 (s, 2H, 5-CH2); 13C NMR (101 MHz, CDCl3) δ (ppm) 181.64 (2-CS), 163.32 (4 and 
5-CO), 138.75 (ArC), 129.68 (ArCH), 129.20 (ArCH), 128.64 (ArCH), 41.23 (5-CH2). 
4.1.3. 5-Benzylidenepyrimidines 2a-e [37]. A stirred mixture of compound 1a-d (1.00 mmol) and 
benzaldehyde (1.00 mmol) in water (5 mL) was refluxed for 2 hours. After cooling, the formed product was 
filtered, washed with water, ethanol and diethyl ether to give the following 5-benzylidenepyrimidines: 
4.1.3.1. 5-(2-Nitrobenzylidene)-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (2a). From 
1,3-diphenylthiobarbituric acid (1a) and 2-nitrobenzaldehyde;Yield 90%; pale orange solid. mp 235 °C dec. 
(lit [60] 232 °C); IR υmax (cm-1) 3032, 1717, 1691, 1624, 1607, 1591, 1520, 1486, 1353, 1325, 1265, 1189, 
1156, 788, 781, 752, 722, 692; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.80 (s, 1H, 5-CCH), 8.19 (d, J = 8.2 
Hz, 1H), 7.71 (t, J = 7.5 Hz, 1H), 7.59 (t, J = 7.9 Hz, 2H), 7.45 (t, J = 7.6 Hz, 2H), 7.40–7.28 (m, 6H), 7.20 
(d, J = 7.7 Hz, 2H); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 181.43 (2-CS), 160.28 (CO), 158.81 (CO), 
155.03 (5-CCH), 146.20 (2’-ArC), 140.02 (ArC), 139.72 (ArC), 134.04 (5’-ArCH), 131.76 (1’-ArC), 130.40 
(4’-ArCH), 130.16 (6’-ArCH), 129.05 (ArCH), 128.88 (ArCH), 128.85 (ArCH), 128.83 (ArCH), 128.28 
(ArCH), 128.10 (ArCH), 124.12 (3’-ArCH), 121.30 (5-C). 
4.1.3.2. 5-(2-Nitrobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (2b). From thiobarbituric 
acid (1b) and 2-nitrobenzaldehyde; Yield 90%; pale yellow solid; mp 239–241 °C (lit [61] 246-250 °C); IR 
υmax (cm-1) 3255, 3156, 2876, 1718, 1692, 1626, 1540, 1513, 1439, 1351, 1288, 1203, 1141, 785, 759, 732; 1H 
NMR (400 MHz, DMSO-d6) δ (ppm) 12.56 (s, 1H, NH), 12.33 (s, 1H, NH), 8.63 (s, 1H, 5-CCH), 8.24 (dd, J 
= 8.3 and 1.0 Hz, 1H, 3’-ArCH), 7.80 (td, J = 7.6 and 1.1 Hz, 1H, 5’-ArCH), 7.72–7.66 (m, 1H, 4’-ArCH), 
7.62 (dt, J = 7.7 and 1.2 Hz, 1H, 6’-ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 179.05 (2-CS), 160.63 
(CO), 159.18 (CO), 153.31 (5-CCH), 146.28 (2’-ArC), 133.77 (5’-ArCH), 131.58 (1’-ArC), 130.49 (4’-
ArCH), 130.39 (6’-ArCH), 124.08 (3’-ArCH), 120.61 (5-C). 
4.1.3.3. 1,3-Dimethyl-5-(2-nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (2c). From 1,3-
dimethylbarbituric acid (1c) and 2-nitrobenzaldehyde; Yield 97%; white solid; mp 158–159 °C (lit [62] 159-
161 °C); IR υmax (cm-1) 3028, 2950, 1663, 1603, 1518, 1457, 1415, 1377, 1342, 1323, 1161, 1092, 1057, 787, 
754, 737, 692; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 8.71 (s, 1H, 5-CCH), 8.26 (dd, J = 8.3 and 1.2 Hz, 
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1H, 3’-ArCH), 7.80 (td, J = 7.6 and 1.3 Hz, 1H, 5’-ArCH), 7.69 (t, J = 7.7 Hz, 1H, 4’-ArCH), 7.53 (d, J = 7.8 
Hz, 1H, 6’-ArCH), 3.25 (s, 3H, NCH3), 3.06 (s, 3H, NCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 161.20 
(CO), 159.96 (CO), 153.65 (5-CCH), 151.10 (2-CO), 146.15 (2’-ArC), 133.90 (5’-ArCH), 132.01 (1’-ArC), 
130.09 (4’-ArCH), 130.02 (6’-ArCH), 124.06 (3’-ArCH), 120.14 (5-C), 28.44 (N-CH3), 27.82 (N-CH3). 
4.1.3.4. 5-(2-Nitrobenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (2d). From barbituric acid (1d) and 2-
nitrobenzaldehyde; Yield 97%; white solid; mp 274-275 °C (lit [61] 274-276 °C); IR υmax (cm-1) 3230, 3070, 
2849, 1739, 1676, 1597, 1516, 1434, 1368, 1341, 1312, 1218, 848, 791, 803, 735, 710; 1H NMR (400 MHz, 
DMSO-d6) δ (ppm) 11.49 (s, 1H, NH), 11.24 (s, 1H, NH), 8.60 (s, 1H, 5-CCH), 8.23 (d, J = 7.9 Hz, 1H, 3’-
ArCH), 7.79 (t, J = 7.4 Hz, 1H, 5’-ArCH), 7.68 (t, J = 7.7 Hz, 1H, 4’-ArCH), 7.57 (d, J = 7.7 Hz, 1H, 6’-
ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 162.38 (CO), 161.20 (CO), 152.45 (5-CCH), 150.26 (2-
CO), 146.28 (2’-ArC), 133.76 (5’-ArCH), 131.72 (1’-ArC), 130.41 (4’-ArCH), 130.16 (6’-ArCH), 124.06 (3’-
ArCH), 120.54 (5-C). 
4.1.3.5. 5-(4-Methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (2e). From barbituric acid (1d) and 
4-methoxybenzaldehyde; Yield 92%; yellow solid; mp 286-289 °C (lit [37] 297-300 °C); IR υmax (cm-1) 3046, 
2838, 1745, 1698, 1651, 1601, 1567, 1532, 1509, 1444, 1431, 1393, 1355, 1316, 1266, 1215, 1179, 1117, 
1041, 1001, 834, 790, 752, 691, 631; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.29 (s, 1H, NH), 11.17 (s, 
1H, NH), 8.37 (d, J = 8.9 Hz, 2H, 2’ and 6’-ArCH), 8.25 (s, 1H, 5-CCH), 7.06 (d, J = 9.2 Hz, 2H, 3’ and 5’-
ArCH), 3.87 (s, 3H, CH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 163.91 (CO), 163.44 (CO), 162.18 (4’-
ArCOCH3), 154.94 (5-CCH), 150.20 (2-CO), 137.49 (2’ and 6’-ArCH), 125.16 (1’-ArC), 115.56 (5-C), 
113.95 (3’ and 5’-ArCH), 55.70 (O-CH3). 
4.1.4. 5-(4-Methoxybenzyl)pyrimidine-2,4,6(1H,3H,5H)-trione (3) [38]. To a stirred solution of 5-(4-
methoxybenzylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (2e) (1.00 mmol) in ethanol (30 mL), were added 
little portions of sodium borohydride (3.00 mmol). The reaction was followed by TLC (ethyl acetate) and 
completed after 4 hours at room temperature. The solvent was evaporated to dryness, and water (20 mL) was 
added with the formation of a suspension, which was acidified with 1 M hydrochloric acid until pH 5. The 
formed solid was filtered and recrystallized from methanol. Yield 41%; white solid; mp 194-195 °C (lit. [63] 
205-210 °C); IR υmax (cm-1) 3224, 2966, 2929, 2835, 1743, 1669, 1608, 1566, 1504, 1421, 1390, 1324, 1299, 
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1273, 1249, 1175, 1113, 1093, 1033, 835, 797, 779, 751, 688, 668; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 
11.15 (s, 2H, NH), 6.99 (d, J = 8.4 Hz, 2H, 2’ and 6’-ArCH), 6.81 (d, J = 8.5 Hz, 2H, 3’ and 5’-ArCH), 3.82 
(t, J = 4.8 Hz, 1H, 5-CH), 3.70 (s, 3H, CH3), 3.19 (d, J = 4.8 Hz, 2H, 5-CCH2); 13C NMR (101 MHz, DMSO-
d6) δ (ppm) 170.04 (4 and 6-CO), 158.05 (4’-ArC), 150.56 (2-CO), 130.03 (1’-ArC), 128.93 (2’ and 6’-
ArCH), 113.71 (3’ and 5’-ArCH), 54,94 (O-CH3), 49,57 (5-CH), 32,83 (5-CHCH2). 
4.1.5. 5-Phenylcyanomethylpyrimidines 4a-b [39]. A stirred suspension of compound 1b-c (1.00 mmol) 
and 4-bromobenzaldehyde (1.00 mmol) in water (5 mL) was refluxed for 2 hours. After cooling, sodium 
cyanide (1.00 mmol) was added and the resulting mixture was stirred at 70 °C. The reaction was followed by 
TLC (dichloromethane/methanol 20%) and completed after 1 hour. The reaction mixture was evaporated to 
dryness and the obtained solid was dissolved in an equimixture of methanol and ethyl acetate. The product 
formed after partial evaporation of the solvent was filtered and washed with diethyl ether to give the following 
5-phenylcyanomethylpyrimidines: 
4.1.5.1. Sodium 5-[(4-bromophenyl)(cyano)methyl]-6-oxo-2-thioxo-1,2,3,6-tetrahydropyrimidine-4-olate 
(4a). From thiobarbituric acid (1b); Yield 67%; white solid; mp 310 C dec.; IR υmax (cm-1) 3092, 2881, 2245, 
1592, 1525, 1485, 1418, 1300, 1173, 1010, 789; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 10.72 (s, 2H, 2 × 
NH), 7.47 (d, J = 8.1 Hz, 2H, 2 × ArCH), 7.31 (d, J = 7.9 Hz, 2 × ArCH, 2H), 5.24 (s, 1H, 5-CCH); 13C NMR 
(101 MHz, DMSO-d6) δ (ppm) 173.82 (2-CS), 161.41 (4 and 6-C), 137.61, 130.91 (2 × ArCH), 129.17 (2 × 
ArCH), 120.26, 119.59, 86.08 (5-C), 30.03 (5-CCH); ESI-HRMS Calcd for [M + Na]+ C12H7N3O2Na2SBr 
381.9232, found 381.9223. 
4.1.5.2. Sodium 5-[(4-bromophenyl)(cyano)methyl]-1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidine-4-olate (4b) From 1,3-dimethylbarbituric acid (1c); Yield 77%; white solid; mp 273 
C dec.; IR υmax (cm-1) 3445, 2951, 2247 (CN), 1668 (C=O), 1583 (C=C), 1442, 1317, 1010, 776, 1H NMR 
(400 MHz, DMSO-d6) δ 7.45 (d, J = 8.5 Hz, 2H, 2 × ArCH), 7.31 (d, J = 8.2 Hz, 2H, 2 × ArCH), 5.35 (s, 1H, 
5-CCH), 3.04 (s, 6H, 2 × NCH3); 13C NMR (101 MHz, DMSO-d6) δ 161.10 (4 and 6-C), 152.75 (2-CO), 
138.46, 130.82 (2 × ArCH), 129.17 (2 × ArCH), 120.85, 119.37, 82.03 (5-C), 31.56 (5-CCH), 26.97 (2 × 
NCH3); ESI-HRMS Calcd for [M + Na]+ C14H11N3O3Na2Br 393.9774, found 393.9760. 
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4.1.6. 5-Acetylpyrimidines (5a-c) [40]. A solution of compound 1a or 1c-d (1.00 mmol) and concentrated 
sulfuric acid (0.100 mmol) was refluxed in acetic anhydride (1.00 mmol) for 1 hour. The reaction was 
followed by TLC (dichloromethane/5% methanol). The reaction mixture was concentrated to half of the initial 
volume and poured onto ice. The formed solid was isolated, washed with hot water, dried and recrystallized 
from ethanol/water (2:1) to give the following 5-acetylpyrimidines: 
4.1.6.1. 5-Acetyl-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (5a). From 1,3-
diphenylthiobarbituric acid (1a); Yield 65%; brown needle crystals; mp 256-257 °C (lit [36] 258-259 °C). IR 
υmax (cm-1) 3051, 3014, 1701, 1635, 1595, 1557, 1488, 1452, 1414, 1364, 1320, 1271, 1240, 1187, 1161, 1094, 
1004, 967, 914, 828, 781, 746, 730, 639, 652, 612; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 7.48 (t, J = 7.4 
Hz, 4H, 3’ and 5’-ArCH), 7.39 (t, J = 7.7 Hz, 2H, 4’-ArCH ), 7.30 (d, J = 7.7 Hz, 4H, 2’ and 6’-ArCH), 2.66 
(s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 196.90 (5-CCCH3), 179.97 (2-CS), 139.68 (1’-
ArC), 129.54 (2’ and 6’-ArCH), 129.32 (3’ and 5’-ArCH), 128.79 (4’-ArCH), 98.72 (5-C), 25.06 (5-CCCH3).  
4.1.6.2. 5-Acetyl-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5b). From 1,3-dimethylbarbituric acid 
(1c); Yield 45%; golden solid; mp 91-92 °C (lit [64] 96.5-98.5 °C); IR υmax (cm-1) 3011, 2963, 1721 (C=O), 
1656 (C=O), 1557, 1494, 1455, 1364, 1337, 1274, 1221, 1164, 1017, 988, 876, 787, 754, 676; 1H NMR (400 
MHz, DMSO-d6) δ (ppm) 3.18 (s, 6H, 2 × NCH3), 2.63 (s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ 
(ppm) 194.96 (5-CCCH3), 150.44 (2-CO), 96.36 (5-C), 28.06 (2 × N-CH3), 24.55 (5-CCCH3); ESI-HRMS 
Calcd for [M + H]+ C8H11N2O4 199.0713, found 199.0726. 
4.1.6.3. 5-Acetylpyrimidine-2,4,6(1H,3H,5H)-trione (5c). From barbituric acid (1d); Yield 83%; brown 
solid; mp 305-307 °C (lit [65] 296-300 °C); IR υmax (cm-1) 3280, 3202, 3115, 3029, 2776, 1779, 1732, 1688, 
1625, 1515, 1463, 1380, 1249, 1207, 1114, 1061, 1028, 966, 800, 741, 650; 1H NMR (400 MHz DMSO-d6) δ 
(ppm) 11.78 (s, 1H, NH), 11.04 (s, 1H, NH), 2.58 (s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ 
(ppm) 195.35 (5-CCCH3), 149.52 (2-CO), 95.89 (5-C), 24.29 (5-CCCH3). 
4.1.7. 5-Hydrazinylethylidenepyrimidines (6a-g) [40]. A stirred suspension of 5-acetylpyrimidine 5a-c 
(1.00 mmol) and the appropriate hydrazine (1.00 mmol) in methanol (20 mL) was refluxed overnight. The 




4.1.7.1. 5-(1-Hydrazinylethylidene)-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (6a). 
From 5-acetyl-1,3-diphenyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (5a) and hydrazine hydrate; Yield 
88%; brown solid; mp 242-243 °C; IR υmax (cm-1) 3331, 3246, 3047, 1662, 1620, 1593, 1552, 1489, 1454, 
1410, 1363, 1355, 1311, 1298, 1284, 1175, 1122, 1066, 1021, 977, 817, 800, 772, 752, 720, 692, 607; 1H 
NMR (400 MHz, DMSO-d6) δ (ppm) 13.35 (s, 1H, 5-CCNH), 7.44-7.20 (m, 12H, ArCH and NH2), 2.61 (s, 
3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 178.47 (2-CS), 166.18 (5-CCCH3), 162.03 (4 and 6-
CO), 140.66 (1’’-ArC), 129.22 (2’’ and 6’’-ArCH), 128.63 (3’’ and 5’’-ArCH), 127.48 (4’’-ArCH), 89.19 (5-
C), 15.91 (5-CCCH3); ESI-HRMS Calcd for [M + H]+ C18H17N4O2S 353.1067, found 353.1069. 
4.1.7.2. 5-(1-Hydrazinylethylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (6b). From 5-acetylpyrimidine-
2,4,6(1H,3H,5H)-trione (5c) and hydrazine hydrate; Yield 86%; yellow solid; mp 300 °C dec.; IR υmax (cm-1) 
3344, 3246, 3004, 1639, 1647, 1609, 1573, 1435, 1374, 1346, 1262, 1242, 1144, 1093, 1037, 977, 923, 872, 
797, 781, 755, 672; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.19 (s, 1H, 5-CCNH), 10.34 (s, 2H, 2 × NH), 
5.55 (s, 2H, NH2), 2,61 (s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 168.35 (5-CCCH3), 
165.64 (4 and 6-CO), 149.87 (2-CO), 86.07 (5-C), 15.19 (5-CCCH3); ESI-HRMS Calcd for [M + Na]+ 
C6H8N4O3Na 207.0489, found 207.0493. 
4.1.7.3. 1,3-Dimethyl-5-(1-(2-phenylhydrazinyl)ethylidene)pyrimidine-2,4,6(1H,3H,5H)-trione (6c). 
From 5-acetyl-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5b) and phenylhydrazine; Yield 50%; white 
needle-like crystals; mp 182-184 °C; IR υmax (cm-1) 3250, 3111, 2997, 2950, 1704, 1672, 1600, 1561, 1459, 
1415, 1374, 1355, 1306, 1252, 1214, 1157, 1123, 1053, 1026, 971, 816, 736, 749, 690, 641; 1H NMR (400 
MHz, DMSO-d6) δ (ppm) 13.36 (s, 1H, 5-CCNH), 8.63 (s, 1H, 1’-ArCNH), 7.27 (t, J = 7.8 Hz, 2H, 3’ and 5’-
ArCH), 6.89 (t, J = 7.4 Hz, 1H, 4’-ArCH), 6.77 (d, J = 7.4 Hz, 2H, 2’ and 6’-ArCH), 3.17 (s, 6H, 2 × NCH3), 
2.70 (s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 174.83 (5-CCCH3) 150.66 (2-CO), 146.43 
(1’-ArC), 129.39 (3’ and 5’-ArCH), 120.71 (4’-ArCH), 112.76 (2’ and 6’-ArCH), 88.57 (5-C), 27.50 (2 x 
NCH3), 16.28 (5-CCCH3); ESI-HRMS Calcd for [M + H]+ C14H17N4O3 289.1295, found 289.1302. 
4.1.7.4. 5-[1-(2-Phenylhydrazinyl)ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6d). From 5-
acetylpyrimidine-2,4,6(1H,3H,5H)-trione (5c) and phenylhydrazine; Yield 92%; dark white solid; mp 307-310 
°C; IR υmax (cm-1) 3267, 3173, 3108, 3064, 3010, 2828, 1712, 1662, 1628, 1601, 1567, 1498, 1458, 1429, 
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1407, 1376, 1359, 1306, 1255, 1241, 1181, 1152, 1048, 832, 799, 772, 746, 691, 651; 1H NMR (400 MHz, 
DMSO-d6) δ (ppm) 13.26 (s, 1H, 5-CCNH), 10.65 (s, 2H, 2 × NH), 8.54 (s, 1H, 1’-ArCNH), 7.26 (t, J = 8.0 
Hz, 2H, 3’ and 5’-ArCH), 6.89 (t, J = 7.8 Hz, 1H, 4’-ArCH), 6.76 (d, J = 7.3 Hz, 2H, 2’ and 6’-ArCH), 2.67 
(s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 174.87 (5-CCCH3), 149.72 (2-CO), 146.59 (1’-
ArC), 129.39 (3’ and 5’-ArCH), 120.66 (4’-ArCH), 112.75 (2’ and 6’-ArCH), 88.20 (5-C), 15.69 (5-CCCH3); 
ESI-HRMS Calcd for [M + H]+ C12H13N4O3 261.0982, found 261.0982. 
4.1.7.5. 1,3-Dimethyl-5-[1-[2-(4-nitrophenyl)hydrazinyl]ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione 
(6e). From 5-acetyl-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5b) and 4-nitrophenylhydrazine; Yield 
67%; brick-colored solid; mp 228-232 °C; IR υmax (cm-1) 3327, 3254, 2948, 2602, 2432, 2160, 1706, 1612, 
1524, 1498, 1455, 1416, 1376, 1357, 1321, 1299, 1270, 1202, 1176, 1104, 971, 836, 797, 794, 690, 658; 1H 
NMR (400 MHz, DMSO-d6) δ (ppm) 13.29 (s, 1H, 5-CCNH), 9.76 (s, 1H, 1’-ArCNH), 8.16 (d, J = 9.8 Hz, 
2H, 3’ and 5’-ArCH), 6.85 (d, J = 9.1 Hz, 2H, 2’ and 6’-ArCH), 3.19 (s, 6H, 2 × NCH3), 2.66 (s, 3H, 5-
CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 175.81 (1’-ArC), 152.80 (5-CCCH3), 151.07 (2-CO), 
140.09 (4’-ArC), 126.51 (3’ and 5’-ArCH), 111.82 (2’ and 6’-ArCH), 89.98 (5-C), 28.03 (2 × N-CH3), 16.77 
(5-CCCH3); ESI-HRMS Calcd for [M + H]+ C14H16N5O5 334.1146, found 334.1148. 
4.1.7.6. 5-[1-[2-(2,4-Dinitrophenyl)hydrazinyl]ethylidene]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-
trione (6f). From 5-acetyl-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (5b) and 2,4-
dinitrophenylhydrazine; Yield 83%; mp 245-247 °C; IR υmax (cm-1) 3362, 3093, 2952, 1705, 1650, 1615, 
1594, 1558, 1538, 1509, 1455, 1360, 1332, 1315, 1275, 1237, 1207, 1157, 1142, 1114, 1060, 972, 923, 850, 
817, 754, 744, 715, 651, 620; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.25 (s, 1H, 5-CCNH), 10.64 (s, 1H, 
1’-ArCNH), 8.89 (d, J = 2.7 Hz, 1H, 3’-ArCH), 8.38 (dd, J = 9.4 and 2.7 Hz, 1H, 5’-ArCH), 7.17 (d, J = 9.5 
Hz, 1H, 6’-ArCH), 3.20 (s, 6H, 2 × NCH3), 2.65 (s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 
176.01 (5-CCCH3), 150.59 (2-CO), 146.98 (1’-ArC), 137.80 (4’-ArC), 130.38 (2’-ArC), 130.37 (5’-ArCH), 
122.88 (3’-ArCH), 115.37 (6’-ArCH), 90.30 (5-C), 27.65 (2 × N-CH3), 16.73 (5-CCCH3); ESI-HRMS Calcd 
for [M + Na]+ C12H10N6O7Na 373.0503, found 373.0498. 
4.1.7.7. 5-[1-[2-(2,4-Dinitrophenyl)hydrazinyl]ethylidene]pyrimidine-2,4,6(1H,3H,5H)-trione (6g). From 
5-acetylpyrimidine-2,4,6(1H,3H,5H)-trione (5c) and 2,4-dinitrophenylhydrazine; Yield 87%; mp 342 °C dec.; 
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IR υmax (cm-1) 3325, 3231, 3094, 3033, 2797, 1710, 1682, 1634, 1616, 1591, 1505, 1455, 1334, 1313, 1272, 
1234, 1175, 1143, 1127, 1059, 1035, 925, 912, 805, 765, 740, 714, 661, 634; 1H NMR (400 MHz, DMSO-d6) 
δ (ppm) 13.22 (s, 1H, 5-CCNH), 10.95 (s, 1H, NH), 10.67 (s, 1H, NH), 10.57 (s, 1H, 1’-ArCNH), 8.89 (d, J = 
2.6 Hz, 1H, 3’-ArCH), 8.38 (dd, J = 9.5 and 2.6 Hz, 1H, 5’-ArCH), 7.20 (d, J = 9.5 Hz, 1H, 6’-ArCH), 2.62 
(s, 3H, 5-CCCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 175.82 (5-CCCH3), 149.63 (2-CO), 147.10 (1’-
ArC), 137.79 (4’-ArC), 130.89 (2’-ArC), 130.42 (5’-ArC), 122.89 (3’-ArCH), 115.45 (6’-ArCH), 89.99 (5-C), 
16.08 (5-CCCH3); ESI-HRMS Calcd for [M + H]+ C14H15N6O7 379.0997, found 379.0992. 
4.1.8. 5-Phenylaminomethylenepyrimidines (7a-j). Obtained from the corresponding compounds 1a-c and 
anilines by the reaction conditions A or B adapted from the literature [27]. All products were isolated by hot 
filtration and washed with hot ethanol and diethyl ether to give the following 5-
phenylaminomethylenepyrimidines. 
Reaction conditions A: A stirred mixture of compound 1b-c (1.00 mmol) and triethyl orthoformate 
(1.00 mmol) was refluxed in butan-1-ol (10 mL). o-Phenylenediamine (1.00 mmol) was added after 
approximately 1 hour, when the color of the reaction mixture changed to red. The resulting mixture was 
refluxed for 3 hours. 
Reaction conditions B: A stirred mixture of compound 1a-d (1.00 mmol), appropriate aniline (1.00 
mmol) and triethyl orthoformate (1 mL) was refluxed in butan-1-ol (10 mL) for 4 hours. 
4.1.8.1. 5-[[(2-Aminophenyl)amino]methylene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7a). From 
thiobarbituric acid (1b) by reaction conditions A; Yield 81%; dark yellow solid; mp 247-249 C; IR υmax (cm-
1) 3429, 3342, 3098, 2998, 2894, 1688, 1616, 1587, 1538, 1471, 1330, 1309, 1162, 1008, 868, 776; 1H NMR 
(400 MHz, DMSO-d6) δ (ppm) 12.14 (s, 1H, NH), 11.99 (s, 1H, NH), 11.89 (d, J = 10.8 Hz, 1H, 1’-Ar-NH), 
8.43 (d, J = 10.8 Hz, 1H,5-CCH), 7.35 (d, J = 7.8 Hz, 1H, 6’-ArCH), 7.05 (t, J = 7.6 Hz, 1H, 4’-ArCH), 6.87 
(d, J = 7.7 Hz, 1H, 3’-ArCH), 6.73 (t, J = 7.5 Hz, 1H, 5’-ArCH), 5.20 (s, 2H, 1’-Ar-NH2); 13C NMR (101 
MHz, DMSO-d6) δ (ppm) 177.70 (2-CS), 164.03 (CO), 161.64 (CO), 153.24 (5-CCH), 140.40 (2’-ArC), 
127.71 (4’-ArCH), 126.02 (1’-ArC), 119.71 (6’-ArCH), 118.37 (5’-ArCH), 117.62 (3’-ArCH), 93.81 (5-C); 




(7b). From thiobarbituric acid (1b) and 2-chloro-5-nitroaniline by reaction conditions B; Yield 97%; dark 
white solid; mp 348-349 C; IR υmax (cm-1) 3074, 2891, 1686, 1620, 1592, 1576, 1517, 1458, 1345, 1317, 
1301, 1161, 1053, 1003, 848, 795, 740; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.57 (d, J = 13.1 Hz, 1H, 
1’-Ar-NH), 12.37 (s, 1H, NH), 12.20 (s, 1H, NH), 8.91 (d, J = 13.0 Hz, 1H, 5-CCH), 8.76 (d, J = 2.6 Hz, 1H, 
6’-CH), 8.06 (dd, J = 8.8 and 2.6 Hz, 1H, 4’-CH), 7.89 (d, J = 8.8 Hz, 1H, 3’-CH); 13C NMR (101 MHz, 
DMSO-d6) δ (ppm) 178.04 (2-CS), 164.56 (CO), 161.06 (CO), 152.92, 147.29, 136.10, 131.07, 129.64, 
120.96, 113.70, 96.17 (5-C). ESI-HRMS Calcd for [M + H]+ C11H8ClN4O4S 326.9949, found 326.9947. 
4.1.8.3. 5-[[(2-Chloro-5-nitrophenyl)amino]methyleno]-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione 
(7c). From 1,3-dimethylbarbituric acid (1c) and 2-chloro-5-nitroaniline by reaction conditions B; Yield 92%; 
white solid; mp 257-259 C; IR υmax (cm-1) 3068, 2956, 1731, 1631, 1599, 1573, 1528, 1498, 1466, 1419, 
1344, 1293, 1204, 1086, 1053, 1000, 882, 825, 740; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.52 (s, 1H, 1’-
Ar-NH), 8.93 (s, 1H, 5-CCH), 8.74 (d, J = 2.4 Hz, 1H, 6’-Ar-CH), 8.06 (dd, J = 8.8 and 2.4 Hz, 1H, 4’-Ar-
CH), 7.89 (d, J = 8.8 Hz, 1H, 3’-Ar-CH), 3.23 (s, 6H, 2 × NCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 
164.67 (CO), 161.38 (CO), 152.26, 151.14 (2-CO), 147.31, 136.26, 131.02, 129.46, 120.59, 113.26, 95.00 (5-
C), 27.66 (NCH3), 27.15 (NCH3); ESI-HRMS Calcd for [M + H]+ C13H12ClN4O5 339.0490, found 339.0485. 
4.1.8.4. 5-[[(2-Chloro-4-nitrophenyl)amino]methyleno]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione 
(7d). From thiobarbituric acid (1b) and 2-chloro-4-nitroaniline by reaction conditions B; Yield 91%; yellow 
solid; mp 365 C dec.; IR υmax (cm-1) 3332, 3053, 2880, 1698, 1650, 1575, 1506, 1457, 1347, 1302, 1288, 
1267, 1139, 815, 744, 731; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.63 (d, J = 12.9 Hz, 1H, 1’-Ar-NH), 
12.44 (s, 1H, NH), 12.27 (s, 1H, NH), 8.83 (d, J = 12.9 Hz, 1H, 5-CCH), 8.48 (d, J = 2.2 Hz, 1H, 3’-ArCH), 
8.25 (dd, J = 9.2 and 1.9 Hz, 1H, 5’-ArCH), 8.19 (d, J = 9.2 Hz, 1H, 6’-ArCH); 13C NMR (101 MHz, DMSO-
d6) δ (ppm) 178.13 (2-CS), 164.48 (CO), 160.99 (CO), 151.47 (5-CCH), 144.11, 140.41, 125.45, 124.03, 
123.08, 117.96, 97.31 (5-C); ESI-HRMS Calcd for [M + H]+ C11H8ClN4O4S 326.9949, found 326.9947. 
4.1.8.5. 5-[[(2-Chlorophenyl)amino]methyleno]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7e). From 
thiobarbituric acid (1b) and 2-chloroaniline by reaction conditions B; Yield 93%; pale yellow solid; mp 357-
358 C; IR υmáx (cm-1) 3106, 3008, 2894, 2562, 1680, 1621, 1599, 1588, 1571, 1536, 1496, 1442, 1316, 1285, 
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1157, 1053, 1000, 854, 802, 767; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.53 (d, J = 13.4 Hz, 1H, 1’-Ar-
NH), 12.31 (s, 1H, NH), 12.14 (s, 1H, NH), 8.74 (d, J = 13.4 Hz, 1H, 5-CCH), 7.93 (d, J = 8.1 Hz, 1H, 
ArCH), 7.62 (dd, J = 8.0 and 1.1 Hz, 1H, ArCH), 7.45 (t, J = 7.7 Hz, 1H, ArCH), 7.29 (td, J = 7.7 and 1.1 
Hz, 1H, ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 177.93 (2-CS), 164.49 (CO), 161.26 (CO), 151.86 
(5-CCH), 134.81, 130.00, 128.82, 127.22, 123.15, 118.18, 95.27 (5-C); ESI-HRMS Calcd for [M + H]+ 
C11H9ClN3O2S 282.0098, found 282.0095. 
4.1.8.6. 5-[[(2-Nitrophenyl)amino]methylene]-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (7f). From 
thiobarbituric acid (1b) and 2-nitroaniline by reaction conditions B; Yield 98%; yellow solid; mp 330 C dec.; 
IR υmax (cm-1) 3121, 3062, 2899, 1684, 1633, 1587, 1567, 1532, 1511, 1436, 1337, 1299, 1261, 1151, 991, 
856, 790, 740; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.33 (d, J = 13.3 Hz, 1H, 1’-Ar-NH), 12.32 (s, 1H, 
NH), 12.18 (s, 1H, NH), 8.72 (d, J = 13.3 Hz, 1H, 5-CCH), 8.26 (dd, J = 8.4 and 1.0 Hz, 1H, ArCH), 8.09 (d, 
J = 8.2 Hz, 1H, ArCH), 7.86 (td, J = 7.9 and 1.1 Hz, 1H, ArCH), 7.47 (td, J = 7.8 and 1.0 Hz, 1H, ArCH); 13C 
NMR (101 MHz, DMSO-d6) δ (ppm) 178.10 (2-CS), 163.57 (CO), 161.35 (CO), 151.86 (5-CCH), 138.03, 
136.23, 133.94, 126.20, 125.98, 119.60, 96.75 (5-C); ESI-HRMS Calcd for [M + H]+ C11H9N4O4S 293.0339, 
found 293.0336. 
4.1.8.7. 2-[[(4,6-Dioxo-1,3-diphenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]amino]benzoic 
acid (7g). From 1,3-diphenylthiobarbituric acid (1a) and 2-aminobenzoic acid by reaction conditions B; Yield 
83%; yellow solid; mp 322-324 C; IR υmáx (cm-1) 3400 to 2700 (broad), 3061, 1689, 1660, 1644, 1607, 1569, 
1439, 1324, 1290, 1259, 1208, 1147, 1070, 753, 723, 691; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 13.82 (s, 
1H, 2’-Ar-COOH), 13.57 (d, J = 14.2 Hz, 1H, 1’-Ar-NH), 8.83 (d, J = 14.1 Hz, 1H, 5-CCH), 8.03 (dd, J = 
7.9 and 1.8 Hz, 1H, ArCH), 7.88 (d, J = 8.4 Hz, 1H, ArCH), 7.73 (td, J = 7.6 and 1.2 Hz, 1H, ArCH), 7.52–
7.43 (m, 4H, Ar-CH), 7.42–7.31 (m, 5H, ArCH), 7.29 (d, 2H, J = 7.2 Hz, ArCH); 13C NMR (101 MHz, 
DMSO-d6) δ (ppm) 180.74 (2-CS), 167.30 (2’-Ar-COOH), 161.92 (CO), 161.05 (CO), 152.23 (5-CCH), 
140.30, 139.66, 139.33, 134.58, 131.68, 129.27, 129.09, 128.90, 128.84, 128.00, 127.88, 125.81, 119.30, 
117.50, 96.12 (5-C); ESI-HRMS Calcd for [M + Na]+ C24H17N3O4NaS 466.0832, found 466.0823. 
4.1.8.8. 2-[[(4,6-Dioxo-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]amino]benzoic acid (7h). 
From thiobarbituric acid (1b) and 2-aminobenzoic acid by reaction conditions B; Yield 97%; dark white solid; 
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mp 365 C dec. (lit [27] 340-344 C); IR υmax (cm-1) 3142 to 2511 (broad), 3142, 3041, 2966, 2892, 1676, 
1602, 1581, 1527, 1457, 1437, 1348, 1321, 1288, 1251, 1158, 1008, 858, 757; 1H NMR (400 MHz, DMSO-
d6) δ (ppm) 13.86 (s, 1H, 2’-Ar-COOH), 13.53 (d, J = 14.0 Hz, 1H, 1’-Ar-NH), 12.14 (s, 1H, NH), 12.05 (s, 
1H, NH), 8.67 (d, J = 14.0 Hz, 1H, 5-CCH), 8.03 (d, J = 7.7 Hz, 1H, ArCH), 7.86 (d, J = 8.4 Hz, 1H, ArCH), 
7.70 (t, J = 7.5 Hz, 1H, ArCH), 7.35 (t, J = 7.6 Hz, 1H, ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 
178.00 (2-CS), 167.61 (2’-Ar-COOH), 162.92 (CO), 161.78 (CO), 150.92 (5-CCH), 139.59, 134.56, 131.67, 
125.50, 118.91, 117.30, 95.48 (5-C). 
4.1.8.9. 2-[[(1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]amino]benzoic acid 
(7i). From 1,3-dimethylbarbituric acid (1c) and 2-aminobenzoic acid by reaction conditions B; Yield 77%; 
pale yellow needle crystals; mp 314-315 C (lit [66] 210 C); IR υmax (cm-1) 3300 to 2600 (broad), 3083, 1715, 
1644, 1602, 1577, 1450, 1355, 1315, 1197, 1142, 1072, 1013, 869, 789, 752; 1H NMR (400 MHz, DMSO-d6) 
δ (ppm) 13.60 (s, 1H, 2’-Ar-COOH), 13.46 (d, J = 14.1 Hz, 1H, 1’-Ar-NH), 8.67 (d, J = 13.9 Hz, 1H, 5-
CCH), 8.01 (d, J = 7.7 Hz, 2H, ArCH), 7.79 (d, J = 8.4 Hz, 1H, ArCH), 7.69 (t, J = 7.7 Hz, 1H, ArCH), 7.32 
(t, J = 7.5 Hz, 1H, ArCH), 3.18 (d, J = 3.1 Hz, 6H, 2 × NCH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 
167.58 (2’-Ar-COOH), 163.04 (CO), 162.06 (CO), 151.41 (5-CCH), 150.40 (2-CO), 139.81, 134.53, 131.66, 
125.09, 118.69, 116.83, 94.19 (5-C), 27.64 (NCH3), 27.03 (NCH3).  
4.1.8.10. 2-[[(2,4,6-Trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]amino]benzoic acid (7j). 
From barbituric acid (1d) and 2-aminobenzoic acid by reaction conditions B; Yield 84%; white solid; mp 365 
C dec. (lit [27] 310-314 C); IR υmax (cm-1) 3163 to 2514 (broad), 3136, 3084, 2815, 1729, 1673, 1614, 1593, 
1573, 1503, 1458, 1439, 1420, 1350, 1324, 1290, 1255, 941, 856, 795, 758; 1H NMR (400 MHz, DMSO-d6) δ 
(ppm) 13.75 (s, 1H, 2’-Ar-COOH), 13.38 (d, J = 13.9 Hz, 1H, 1’-Ar-NH), 10.96 (s, 1H, NH), 10.88 (s, 1H, 
NH), 8.62 (d, J = 13.8 Hz, 1H, 5-CCH), 8.02 (d, J = 7.6 Hz, 1H, ArCH), 7.81 (d, J = 8.4 Hz, 1H, ArCH), 
7.69 (t, J = 7.9 Hz, 1H, ArCH), 7.32 (t, J = 7.6 Hz, 1H, ArCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 
167.69 (2’-Ar-COOH), 165.08 (CO), 163.72 (CO), 150.71 (5-CCH), 149.85 (2-CO), 139.97, 134.57, 131.69, 
124.97, 118.57, 116.87, 94.26 (5-C). 
4.1.9. 1-[(Pyrimidin-5-ylidene)methyl]ureas 8a-g. A stirred mixture of compound 1a-d (1.00 mmol), 
urea/thiourea (1.00 mmol) and triethyl orthoformate (1.50 mmol) was refluxed in butan-1-ol (10 mL) for 4 
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hours. The formed product was filtered and washed with diethyl ether to give the following 1-(pyrimidin-5-
ylidene)ureas: 
4.1.9.1. 1-[(4,6-Dioxo-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]urea (8a). From thiobarbituric 
acid (1b) and urea; Yield 77 %; reddish solid; mp 298-300 C; IR υmax (cm-1) 3406, 3147, 2889, 1730, 1693, 
1643, 1529, 1375, 1259, 1149, 815, 757 ; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.19 (s, 1H, NH), 12.13 
(1H, s, NH), 11.24 (d, J = 13.2 Hz, 1H, 5-CCHNH), 8.54 (d, J = 13.1 Hz, 1H, 5-CCH), 7.88 (s, 1H, NH2), 
7.56 (s, 1H, NH2); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 178.46 (2-CS), 163.01 (CO), 161.73 (CO), 
152.03 (NHCNH2), 151.03 (5-CCH), 96.12 (5-C); ESI-HRMS Calcd for [M + H]+ C6H7N4O3S 215.0239, 
found 215.0237. 
4.1.9.2. 1-[(1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]urea (8b). From 1,3-
dimethylbarbituric acid (1c) and urea; Yield 52%; yellow solid; mp 260-261 C; IR υmax (cm-1) 3371, 3278, 
3197, 1704, 1666, 1635, 1560, 1406, 1371, 1255, 1085; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.23 (d, J = 
13.1 Hz, 1H, 5-CCHNH), 8.61 (d, J = 13.1 Hz, 1H, 5-CCH), 7.82 (s, 1H, NH2), 7.47 (s, 1H, NH2), 3.17 (d, J 
= 3.7 Hz, 6H, 2 × N-CH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 163.24 (CO), 161.95 (CO), 152.17 
(NHCNH2), 151.27 (5-CCH), 150.67 (2-CO), 94.90 (5-C), 27.66 (N-CH3), 27.02 (N-CH3); ESI-HRMS Calcd 
for [M + H]+ C8H11N4O4 227.0780, found 227.0780. 
4.1.9.3. 1-[(2,4,6-Trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]urea (8c). From barbituric acid (1d) 
and urea; Yield 71%; light-brown solid; mp 248-250 C; IR υmax (cm-1) 3411, 3172, 1733, 1703, 1629, 1569, 
1384, 1305, 1272, 792; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.10 (d, J = 13.1 Hz, 1H, 5-CCHNH), 11.06 
(s, 1H, NH), 10.97 (s, 1H, NH), 8.51 (d, J = 13.1 Hz, 1H, 5-CCH), 7.83 (s, 1H, NH2), 7.46 (s, 1H, NH2); 13C 
NMR (101 MHz, DMSO-d6) δ (ppm) 165.22 (CO), 163.57 (CO), 152.33 (NHCNH2), 150.61 (5-CCH), 149.91 
(2-CO), 95.08 (5-C); ESI-HRMS Calcd for (M+ + Na) C6H6N4O4Na 221.0281, found 221.0282. 
4.1.9.4. 1-[(4,6-Dioxo-1,3-diphenyl-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]thiourea (8d). 
From 1,3-diphenylthiobarbituric acid (1a) and thiourea; Yield 85%; orange solid; mp 259-261 C (lit 263-264 
C [67]); IR υmax (cm-1) 3442, 3263, 3172, 3051, 1685, 1654, 1591, 1487, 1402, 1321, 1217, 1190, 1153, 823, 
688; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.13 (d, J = 11.7 Hz, 1H, 5-CCHNH), 9.72 (s, 1H, NH2), 9.44 
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(s, 1H, NH2), 9.28 (d, J = 11.7 Hz, 1H, 5-CCH), 7.49-7.27 (m, 10H, ArCH); 13C NMR (101 MHz, DMSO-d6) 
δ (ppm) 181.16 (NHCNH2), 180.79 (2-CS), 162.01 (CO), 160.72 (CO), 153.88 (5-CCH), 139.94 (ArC), 
139.29 (ArC), 128.96 (2 × ArCH), 128.91 (2 × ArCH), 128.80 (2 × ArCH), 128.75 (2 × ArCH), 128.00 
(ArCH), 127.94 (ArCH), 98.49 (5-C); ESI-HRMS Calcd for [M + H]+ C18H15N4O2S2 383.0636, found 
383.0635. 
4.1.9.5. 1-[(4,6-Dioxo-2-thioxotetrahydropyrimidin-5(2H)-ylidene)methyl]thiourea (8e). From 
thiobarbituric acid (1b) and thiourea; Yield 74%; red solid; mp 252 C dec.; IR υmax (cm-1) 3284, 3136, 1695, 
1664, 1574, 1506, 1413, 1259, 1143, 1012, 997, 804; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 12.32 (s, 1H, 
NH), 12.23 (s, 1H, NH), 11,94 (d, J = 13.1 Hz, 1H, 5-CCHNH), 9.70 (s, 1H, NH2), 9.55 (s, 1H, NH2), 9.11 (d, 
J = 13.1 Hz, 1H, 5-CCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 181.31 (NHCNH2), 178.48 (2-CS), 
163.05 (CO), 161.50 (CO), 152.57 (5-CCH), 97.95 (5-C); ESI-HRMS Calcd for [M + H]+ C6H7N4O2S2 
231.0010, found 231.0013. 
4.1.9.6. 1-[(1,3-Dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]thiourea (8f). From 1,3-
dimethylbarbituric acid (1c) and thiourea; Yield 89%; yellow solid; mp 267-270 C; IR υmax (cm-1) 3290, 
3145, 1716, 1635, 1589, 1469, 1429, 1338, 1230, 1186, 1086, 798, 754; 1H NMR (400 MHz, DMSO-d6) δ 
(ppm) 11.95 (d, J = 12.4 Hz, 1H, 5-CCHNH), 9.59 (s, 1H, NH2), 9.48 (s, 1H, NH2), 9.19 (d, J = 12.4 Hz, 1H, 
5-CCH), 3.19 (d, J = 3.3 Hz, 6H, 2 × N-CH3); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 181.46 (NHCNH2), 
163.30 (CO), 161.70 (CO), 152.35 (5-CCH), 151.14 (2-CO), 95.78 (5-C), 27.76 (N-CH3), 27.17 (N-CH3); 
ESI-HRMS Calcd for [M + H]+ C8H11N4O3S 243.0552, found 243.0551. 
4.1.9.7. 1-[(2,4,6-Trioxotetrahydropyrimidin-5(2H)-ylidene)methyl]thiourea (8g). From barbituric acid 
(1d) and thiourea; Yield: 86%; light-brown solid; mp 375 C dec.; IR υmax (cm-1) 3280, 3217, 3145, 3045, 
2808, 1733, 1701, 1645, 1571, 1438, 1407, 1247, 1024, 783; 1H NMR (400 MHz, DMSO-d6) δ (ppm) 11.84 
(d, J = 12.3 Hz, 1H, 5-CCHNH), 11.15 (s, 1H, NH), 11.03 (s, 1H, NH), 9.53 (s, 1H, NH2), 9.45 (s, 1H, NH2), 
9.08 (d, J = 12.3 Hz, 1H, 5-CCH); 13C NMR (101 MHz, DMSO-d6) δ (ppm) 181.52 (NHCNH2), 165.17 (CO), 
163.22 (CO), 151.54 (5-CCH), 150.40 (2-CO), 96.96 (5-C); ESI-HRMS Calcd for [M + H]+ C6H7N4O3S 
215.0239, found 215.0238. 
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4.2. In vitro activity 
4.2.1.  Xanthine oxidase inhibitory activity  
4.2.1.1.  Preparation of  sample solutions  
All assayed compounds were dissolved in DMSO in a concentration of 10 mM for the initial screening and 
50 mM for the concentration-response studies. A 10 mM xanthine stock solution was prepared in a 25 mM 
aqueous NaOH solution. All stock solutions were stored at 4 °C and the diluted solutions were prepared in 50 
mM dihydrogen phosphate buffer (pH 7.4) before each experiment. The concentrations in each well were 30 
μM for the initial screening as well as 0.1, 1, 7.5, 15, 30, 50 and 100 μM for the concentration-response 
studies. The final concentration of DMSO in each well was 1%, and no significant interference with the 
enzyme activity was observed (data not shown). 
4.2.1.2.  Experimental procedure  
The xanthine oxidase (XO) activity was spectrophotometrically determined by quantifying the uric acid 
formation from xanthine adapting the methods of Zhao et al. [41] and Gupta et al. [68]. For each essay, 50 μL 
of test solution and 50 μL of a XO bovine serum suspension (0.1 U/mL) were added to each well of a 96-well 
plate followed by a pre-incubation at 37 °C for 5 minutes. The enzymatic reaction started after the addition of 
150 μL of xanthine (0.42 mM) and further incubation at 37 °C during 10 min. The absorbances were 
measured at 295 nm and at every minute, with 20 seconds of a constant and automatic slow stirring before 
each reading. Dihydrogen phosphate buffer (50 mM, pH 7.4) was used as negative control and allopurinol as a 
positive control. In order to discount the absorbance of each compound at this wavelength, a blank sample 
containing 50 μL of test solution and 200 μL of buffer was performed. Three independent experiments, each 
one in triplicate, were performed. The percentage of enzyme inhibition for each compound was calculated 
according to the following formula: 
% of inhibition = [1 - (Abssample – Absblank of sample) / Absnegative control] × 100 
The direct breakdown of uric acid by the synthetized BADs and TBADs 2-8 was spectrophotometrically 
studied in experimental conditions similar to the established in enzymatic inhibition assays. For each assay, 50 
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μL of test solution (60 μM) and 50 μL of uric acid (200 μM) were added to each well of a 96-well plate. The 
absorbances were measured at 295 nm after further incubation at 37 °C during 10 min. In order to discount the 
absorbance of each compound at this wavelength, a blank sample containing 50 μL of test solution and 50 μL 
of buffer was performed. Three independent experiments, each one in triplicate, were performed. No 
significant interference with uric acid levels was observed for any compound under study. 
 
4.2.2.  Radical scavenging activi ty 
4.2.2.1.  Preparation of  sample solutions  
All assayed compounds were dissolved in DMSO in a 10 mM concentration and stored at 4 °C. The diluted 
solutions were prepared in 99.5% ethanol before each experiment. The concentrations in each well were 30 
μM for the initial screening as well as 1, 7.5, 15, 30, 50 and 100 μM for the concentration-response studies.  
4.2.2.2.  Experimental procedure  
The radical scavenging activity was spectrophotometrically determined by the quantification of the DPPH 
reduction extension by the compounds under study, according to Zhao et al.[41] and Nicolaides et al. [42]. 
The reaction mixture contained 100 μL of the test solution and 100 μL of the DPPH solution (0.2 mM). The 
capacity of each compound to reduce DPPH was followed by measuring the absorbance at 517 nm after 20 
and 60 minutes. The solutions remained in the absence of light between measurements. Ethanol was used as 
the negative control and Trolox as the positive control. To discount the absorbance of each compound at 517 
nm, for each test compound a blank was performed where DPPH was replaced by ethanol. Three independent 
experiments were performed, each one in triplicate. The reduction capacity of DPPH was calculated according 
to the following formula: 
% Reduction = [1 - (Abssample - Abssample blank / Absnegative control)] × 100 
4.2.3.  Antibacterial  activi ty  
4.2.3.1.  Sample solutions,  bacteria, stock and growth conditions  
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All the tested compounds were dissolved in DMSO in a concentration of 10 mM, stored at 4 °C, and diluted 
with culture medium before assays. 
The following strains were used in the study: Bacillus cereus ATCC11778, Staphylococcus aureus ATCC 
25923, Escherichia coli ATCC 25922, Klebsiella pneumoniae ATCC 13883, Pseudomonas aeruginosa ATCC 
27853, Salmonella enterica subsp. enterica serovar Typhimurium ATCC 13311 and Acinetobacter baumannii 
LMG 1025. All bacterial cultures were stocked at -80 ºC in medium with 20% glycerol. The bacteria were 
sub-cultured on Müeller Hinton Agar and incubated overnight at 37 ºC prior to each antimicrobial assay. 
 
4.2.3.2.  Determination of  minimum inhibitory concentration (MIC)  
The antibacterial activity of the test compounds was studied by measurement of MIC by broth microdilution 
method according with CLSI guidelines (M7-A6). The compounds were two-fold serially diluted in a 96-well 
plate with Müeller Hinton Broth (MHB) to a volume of 50 µL, to give a final concentration range from 200 to 
1.56 µM. The maximum DMSO concentration was 2% (v/v). Bacterial suspensions were prepared from 
overnight culture using sterile saline solution, i.e. NaCl 0.85% (w/v), adjusted to 0.5 McFarland and diluted 
with MHB. Then 50 µL of suspension was added to each well to a final concentration of about 5×105 colony 
forming units/ml, and the plate was incubated at 37 ºC for 24 h. Sterility, solvent and growth controls were 
included in the assays, also tetracycline was used as reference. The MIC was defined as the lowest 
concentration at which no growth was visually observed. Each test was carried out at least three independent 
times and modal MIC values were selected. 
4.2.4.  Cytotoxicity in human cell  l ines  
4.2.4.1.  Preparation of  sample solutions  
All the tested compounds were dissolved in DMSO in a concentration of 10 mM and stored at 4 °C. From 
this solution, several solutions of the compounds in study were prepared by their adequate dilutions in the 
complete culture medium before each experiment. The maximum DMSO concentration in the studies was 1% 
(v/v), a concentration with no significant effect on cell proliferation (data not shown). 
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4.2.4.2.  Cells cultures  
The cells used in this study were human breast cancer cells (MCF-7) and normal human dermal fibroblasts 
(NHDF) and were obtained from American Type Culture Collection (ATCC). These cells were maintained at 
37 ºC in a humidified atmosphere containing 5% CO2. MCF-7 cells were cultured in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% 
antibiotic/antimycotic (10,000 units/mL penicillin, 10 mg/mL streptomycin and 25 µg/mL amphotericin B). 
The RPMI medium supplemented with 10% fetal bovine serum (FBS), L-glutamine (2 mM), HEPES (10 
mM), sodium pyruvate (1 mM) and 1% antibiotic/antimycotic was used to culture NHDF cells. The cells used 
in the experiments were used in passages 26 to 31 (MCF-7) and 6 to 11 (NHDF). 
4.2.4.3.  MTT assay  
The cell proliferation was evaluated by quantifying the extent of the reduction of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) according to a previously described procedure [52]. Cells were 
seeded in 96-well plates (2×104 cells/mL) in the culture medium and after 48 h of adherence they were treated 
with the different compounds and concentrations under study for 72 h. Untreated cells were used as negative 
control and 5-FU as positive control. At the end of incubation, the medium was removed and replaced with 
fresh culture medium and MTT solution [5 mg/mL in phosphate buffer saline (NaCl 137 mM, KCl 2.7 mM, 
Na2HPO4 10 mM and KH2PO4 1.8 mM), pH 7.4] and further incubated at 37 C during 4 h. Then, the 
medium-containing MTT was removed and formazan crystals were dissolved with DMSO followed by 
absorbance readings at 570 nm. The cytotoxicity was expressed as the relative cell proliferation in percentage 
in comparison with the negative control cells. 
 
4.2.5. Statistics 
The results are expressed as mean values ± standard error of the mean (SEM) and are representative of least 
two independent experiments. The difference between groups was considered statistically significant at 
p<0.05 (Student´s t-test). The IC50 values were calculated by sigmoidal fitting analysis considering a 95% 




4.3.  In silico simulations 
The structures of tested compounds were manually drawn in ChemBioDraw 13.0 software and the SMILES 
notation was obtained for each molecule. To calculate the parameters of Lipinski’s rule of five, 
pharmacokinetic (absorption, distribution, metabolism and excretion) and toxicity properties, the SMILES 
notation in PkCSM online software (available from http://bleoberis.bioc.cam.ac.uk/pkcsm/prediction, 
accessed at 04.04.17) was employed [54]. 
Acknowledgments 
This work is supported by FEDER funds through the POCI - COMPETE 2020 - Operational Programme 
Competitiveness and Internationalization in Axis I - Strengthening research, technological development and 
innovation (Project POCI-01-0145-FEDER-007491) and National Funds by FCT - Foundation for Science 
and Technology (Project UID/Multi /00709/2013). The authors also acknowledge the contribution of Dr. 
Adriana Santos for the revision of written English.  
References  
[1] J.W. Dundee, P.D.A. McIlroy, The history of the barbiturates, Anaesthesia, 37 (1982) 726–734. 
[2] F. López-Muñoz, R. Ucha-Udabe, C. Alamo, The history of barbiturates a century after their clinical 
introduction, Neuropsychiatric Disease and Treatment, 1 (2005) 329. 
[3] T.L. Lemke, D.A. Williams, Sedative-Hypnotics, in:  Foye's Principles of Medicinal Chemistry, Wolters 
Kluwer Health, 2012, pp. 485-507. 
[4] J. Wang, M.W. Radomski, C. Medina, J.F. Gilmer, MMP inhibition by barbiturate homodimers, 
Bioorganic & Medicinal Chemistry Letters, 23 (2013) 444-447. 
[5] K.M. Khan, M. Khan, A. Karim, M. Taha, N. Ambreen, A. Gojayev, S. Perveen, M.I. Choudhary, 
Xanthine oxidase inhibition by 5-aryledene N,N’-dimethylbarbituric acid derivatives, Journal of the Chemical 
Society of Pakistan, 35 (2013) 495-498. 
[6] R.M. Shaker, E.A. Ishak, Barbituric acid utility in multi-component reactions, Zeitschrift für 
Naturforschung, 66b (2011) 1189 – 1201. 
36 
 
[7] G.M. Ziarani, F. Aleali, N. Lashgari, Recent applications of barbituric acid in multicomponent reactions, 
RSC Advances, 6 (2016) 50895-50922. 
[8] K.T. Mahmudov, M.N. Kopylovich, A.M. Maharramov, M.M. Kurbanova, A.V. Gurbanov, A.J.L. 
Pombeiro, Barbituric acids as a useful tool for the construction of coordination and supramolecular 
compounds, Coordination Chemistry Reviews, 265 (2014) 1-37. 
[9] N. Kobra, K. Zahra, Barbituric acids in organic transformations, an outlook to the reaction media, Mini-
Reviews in Organic Chemistry, 14 (2017) 143-173. 
[10] A. Barakat, M.S. Islam, A.M. Al-Majid, S.M. Soliman, Y.N. Mabkhot, Z.A. Al-Othman, H.A. Ghabbour, 
H.-K. Fun, Synthesis of novel 5-monoalkylbarbiturate derivatives: new access to 1,2-oxazepines, Tetrahedron 
Letters, 56 (2015) 6984-6987. 
[11] M. Bararjanian, S. Balalaie, B. Movassagh, A.M. Amani, One-pot synthesis of pyrano[2,3-
d]pyrimidinone derivatives catalyzed by L-proline in aqueous media, Journal of the Iranian Chemical Society, 
6 (2009) 436-442. 
[12] M. Bayat, Y. Bayat, S.S. Asayesh, One-pot synthesis of 2H-pyrano[2,3-d]pyrimidine derivatives, 
Monatshefte für Chemie - Chemical Monthly, 143 (2011) 479-483. 
[13] V.D. Dyachenko, R.P. Tkachev, Functionally-substituted alkoxyethylenes in reactions with nucleophiles: 
Part 2. Synthesis of noncyclic structures, benzene derivatives, 5-, 7-membered, and macroheterocycles, 
Russian Journal of Organic Chemistry, 42 (2006) 149–171. 
[14] R. Ghahremanzadeh, F. Fereshtehnejad, A. Bazgir, Chromeno[2,3-d]pyrimidine-triones synthesis by a 
three-component coupling reaction, Chemical and Pharmaceutical Bulletin, 58 (2010) 516-520. 
[15] M.A. Ismail, S. Al-Shihry, R.K. Arafa, U. El-Ayaan, Synthesis, antimicrobial activity and molecular 
modeling study of substituted 5-aryl-pyrimido[5,4-c]quinoline-2,4-diones, Journal of Enzyme Inhibition and 
Medicinal Chemistry, 28 (2013) 530-538. 
[16] R.N. Kumar, T. Suresh, P.S. Mohan, A convenient one-pot synthesis of 




[17] N.D. Moirangthem, W.S. Laitonjam, A new and facile synthetic approach to substituted 2-
thioxoquinazolin-4-ones by the annulation of a pyrimidine derivative, Beilstein Journal of Organic Chemistry, 
6 (2010) 1056-1060. 
[18] A. Pati, P. Majumdar, S. Garnayak, A.K. Behera, R.K. Behera, Regiospecific ring closure reactions of 
1,3-diphenylthiobarbituric acid and dimedone: Formation of spiro vs fused heterocycles, Indian Journal of 
Chemistry - Section B Organic and Medicinal Chemistry, 53 (2013) 384-391. 
[19] H.S. Thokchom, A.D. Nongmeikapam, W.S. Laitonjam, Synthesis of fused pyrazolo-, isoxazolo-, 
pyrimido-, and pyridopyrimidines, Canadian Journal of Chemistry, 83 (2005) 1056–1062. 
[20] M. Adib, M. Sayahi, H. Ziyadi, L.-G. Zhu, H. Bijanzadeh, A novel, one-pot, efficient synthesis of 2-
aroyl-1,4-diaryl-7,9-dimethyl-7,9-diazaspiro[4.5]deca-1,3-diene-6,8,10-triones, Synthesis, 2008 (2008) 3289-
3294. 
[21] A.S. Girgis, H. Farag, N.S.M. Ismail, R.F. George, Synthesis, hypnotic properties and molecular 
modeling studies of 1,2,7,9-tetraaza-spiro[4.5]dec-2-ene-6,8,10-triones, European Journal of Medicinal 
Chemistry, 46 (2011) 4964-4969. 
[22] Y. Hu, D.-Q. Shi, An efficient synthesis of new dispiropyrrolidine derivatives via three-component 1,3-
dipolar cycloaddition reaction, Journal of Heterocyclic Chemistry, 50 (2013) E121-E125. 
[23] Z. Huang, Q. Zhao, G. Chen, H. Wang, W. Lin, L. Xu, H. Liu, J. Wang, D. Shi, Y. Wang, An efficient 
synthesis of novel dispirooxindole derivatives via one-pot three-component 1,3-dipolar cycloaddition 
reactions, Molecules, 17 (2012) 12704-12717. 
[24] H.-W. Zhao, T. Tian, B. Li, Z. Yang, H.-L. Pang, W. Meng, X.-Q. Song, X.-Q. Chen, Diastereoselective 
synthesis of dispirobarbiturates through Et3N-catalyzed [3+2] cycloaddition of barbituratebased olefins with 
3-isothiocyanato oxindoles, Journal of Organic Chemistry, 80 (2015) 10380–10385. 
[25] K.M. Khan, M. Khan, A. Ahmad, A. Irshad, L.B.S. Kardono, F. Rahim, S.M. Haider, S. Ahmed, S. 
Parveen, Antibacterial and antifungal activities of 5-arylidene-N,N-dimethylbarbiturates derivatives, Journal 
of the Chemical Society of Pakistan, 36 (2014) 1153-1157. 
[26] H.M. Aly, M.M. Kamal, Efficient one-pot preparation of novel fused chromeno[2,3-d]pyrimidine and 
pyrano[2,3-d]pyrimidine derivatives, European Journal of Medicinal Chemistry, 47 (2012) 18-23. 
38 
 
[27] A. Rauf, S. Shahzad, M. Bajda, M. Yar, F. Ahmed, N. Hussain, M.N. Akhtar, A. Khan, J. Jonczyk, 
Design and synthesis of new barbituric- and thiobarbituric acid derivatives as potent urease inhibitors: 
Structure activity relationship and molecular modeling studies, Bioorganic & Medicinal Chemistry, 23 (2015) 
6049-6058. 
[28] D.M. Neumann, A. Cammarata, G. Backes, G.E. Palmer, B.S. Jursic, Synthesis and antifungal activity of 
substituted 2,4,6-pyrimidinetrione carbaldehyde hydrazones, Bioorganic & Medicinal Chemistry, 22 (2014) 
813-826. 
[29] A. Pati, P. Majumdar, S. Garnayak, A.K. Behera, R.K. Behera, Regiospecific ring closude reactions of 
1,3.diphenylthiobarbituric acid and dimedone: Formation of spiro vs fused heterocycles, Indian Journal of 
Chemistry - Section B Organic and Medicinal Chemistry, 53 (2014) 384-391. 
[30] R. Kumar, Darpan, S. Sharma, R. Singh, Xanthine oxidase inhibitors: a patent survey, Expert Opinion on 
Therapeutic Patents, 21 (2011) 1071-1108. 
[31] A. Šmelcerović, K. Tomović, Ž. Šmelcerović, Ž. Petronijević, G. Kocić, T. Tomašič, Ž. Jakopin, M. 
Anderluh, Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of 
potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and 
toxicity, European Journal of Medicinal Chemistry, 135 (2017) 491-516. 
[32] F. Borges, E. Fernandes, F. Roleira, Progress towards the discovery of xanthine oxidase inhibitors, 
Current Medicinal Chemistry, 9 (2002) 195-217. 
[33] H.S. Virdi, S. Sharma, S. Mehndiratta, P.M. Bedi, K. Nepali, Design, synthesis and evaluation of 2,4-
diarylpyrano[3,2-c]chromen-5(4H)-one as a new class of non-purine xanthine oxidase inhibitors, Journal of 
Enzyme Inhibition and Medicinal Chemistry, (2014) 1-7. 
[34] A. Duarte, S. Ferreira, S. Almeida, F.C. Domingues, Clinical isolates of Acinetobacter baumannii from a 
portuguese hospital: PFGE characterization, antibiotic susceptibility and biofilm-forming ability, Comparative 
Immunology, Microbiology and Infectious Diseases, 45 (2016) 29-33. 
[35] A. Lu, Z. Wang, Z. Zhou, J. Chen, Q. Wang, Application of "hydrogen bonding interaction" in new drug 
development: design, synthesis, antiviral activity, and SARs of thiourea derivatives, Journal of Agricultural 
and Food Chemistry, 63 (2015) 1378-1384. 
39 
 
[36] H. Schulte, Über die kondensation des N,N'-diphenylthioharnstoffes mit malonylchlorid, Chemische 
Berichte, 87 (1954) 820-824. 
[37] M.L. Deb, P.J. Bhuyan, Uncatalysed Knoevenagel condensation in aqueous medium at room 
temperature, Tetrahedron Letters, 46 (2005) 6453-6456. 
[38] Q. Yan, R. Cao, W. Yi, Z. Chen, H. Wen, L. Ma, H. Song, Inhibitory effects of 5-benzylidene barbiturate 
derivatives on mushroom tyrosinase and their antibacterial activities, European Journal of Medicinal 
Chemistry, 44 (2009) 4235-4243. 
[39] E. Soleimani, M.M. Khodaei, N. Batooie, M. Baghbanzadeh, Water-prompted synthesis of alkyl nitrile 
derivatives via Knoevenagel condensation and Michael addition reaction, Green Chemistry, 13 (2011) 566. 
[40] B.S. Jursic, D.M. Neumann, Preparation of 5-formyl- and 5-acetylbarbituric acids, including the 
corresponding Schiff bases and phenylhydrazones, Tetrahedron Letters, 42 (2001) 8435-8439. 
[41] M. Zhao, D. Zhu, D. Sun-Waterhouse, G. Su, L. Lin, X. Wang, Y. Dong, In vitro and in vivo studies on 
adlay-derived seed extracts: phenolic profiles, antioxidant activities, serum uric acid suppression, and xanthine 
oxidase inhibitory effects, Journal of Agricultural and Food Chemistry, 62 (2014) 7771-7778. 
[42] D.N. Nicolaides, D.R. Gautam, K.E. Litinas, D.J. Hadjipavlou-Litina, K.C. Fylaktakidou, Synthesis and 
evaluation of the antioxidant and antiinflammatory activities of some benzo[l]khellactone derivatives and 
analogues, European Journal of Medicinal Chemistry, 39 (2004) 323-332. 
[43] H.J. Tang, X.W. Zhang, L. Yang, W. Li, J.H. Li, J.X. Wang, J. Chen, Synthesis and evaluation of 
xanthine oxidase inhibitory and antioxidant activities of 2-arylbenzo[b]furan derivatives based on salvianolic 
acid C, European Journal of Medicinal Chemistry, 124 (2016) 637-648. 
[44] J.P. Dzoyem, L.J. McGaw, J.N. Eloff, In vitro antibacterial, antioxidant and cytotoxic activity of acetone 
leaf extracts of nine under-investigated Fabaceae tree species leads to potentially useful extracts in animal 
health and productivity., BMC Complementary and Alternative Medicine, 14 (2014) 147-154. 
[45] N. Dilek Özçelik, T. Tunç, R. Çatak Çelik, M. Erzengin, H. Özışık, Synthesis, spectroscopic, crystal 
structure, biological activities and theoretical studies of 2-[(2E)-2-(2-chloro-6-
fluorobenzylidene)hydrazinyl]pyridine, Journal of Molecular Structure, 1135 (2017) 98-105. 
[46] F. Ghanbari Pirbasti, N.O. Mahmoodi, Facile synthesis and biological assays of novel 2,4-disubstituted 
hydrazinyl-thiazoles analogs, Molecular Diversity, 20 (2016) 497-506. 
40 
 
[47] A. Grozav, I.-D. Porumb, I.L. Găină, L. Filip, D. Hanganu, Cytotoxicity and antioxidant potential of 
novel 2-(2-((1H-indol-5yl)methylene)-hydrazinyl)-thiazole derivatives, Molecules, 22 (2017). 
[48] S. Mumtaz, R. Hussain, A. Rauf, M.Q. Fatmi, H. Bokhari, M. Oelgemöller, A.M. Qureshi, Synthesis, 
molecular docking studies, and in vitro screening of barbiturates/thiobarbiturates as antibacterial and 
cholinesterase inhibitors, Medicinal Chemestry Research, 23 (2014) 2715–2726. 
[49] Y.-C. Jeong, M.G. Moloney, Antibacterial Barbituric Acid Analogues Inspired from Natural 3-
Acyltetramic Acids; Synthesis, Tautomerism and Structure and Physicochemical Property-Antibacterial 
Activity Relationships, Molecules, 20 (2015) 3582-3627. 
[50] E. Giziroglu, C. Sarikurkcu, M. Aygün, G. Basbulbul, H.C. Soyleyici, E. Firinci, B. Kirkan, A. Alkis, T. 
Saylica, H. Biyik, Barbiturate bearing aroylhydrazine derivatives: Synthesis, NMR investigations, single 
crystal X-ray studies and biological activity, Journal of Molecular Structure, 1108 (2016) 325-333. 
[51] Tacconelli, E. and Magrini, N. 2017. Global priority list of antibiotic-resistant bacteria to guide research, 
discovery, and development of new antibiotics. Retrieved from World Health Organization website. 
(http://www.who.int/entity/medicines/publications/WHO-PPL-Short_Summary_25Feb-
ET_NM_WHO.pdf?ua=1) (accessed September 6, 2017). 
[52] M. Catarro, J. Serrano, E. Cavalheiro, S. Ramos, A.O. Santos, S. Silvestre, P. Almeida, Novel 4-
acetamide-2-alkylthio-N-acetanilides resembling nimesulide: Synthesis, cell viability evaluation and in silico 
studies, Bioorganic & Medicinal Chemistry, 25 (2017) 4304-4313. 
[53] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and 
cytotoxicity assays, Journal of Immunological Methods, 65 (1983) 55-63. 
[54] D.E. Pires, T.L. Blundell, D.B. Ascher, pkCSM: Predicting small-molecule pharmacokinetic and toxicity 
properties using graph-based signatures, Journal of Medicinal Chemistry, 58 (2015) 4066-4072. 
[55] C.A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability, Journal of 
Pharmacological and Toxicological Methods, 44 (2000) 235-249. 
[56] J.B. Baell, G.A. Holloway, New substructure filters for removal of pan assay interference compounds 
(PAINS) from screening libraries and for their exclusion in bioassays, Journal of Medicinal Chemistry, 53 
(2010) 2719-2740. 
[57] J. Baell, M.A. Walters, Chemical con artists foil drug discovery, Nature, 513 (2014) 481-483. 
41 
 
[58] S.J. Capuzzi, E.N. Muratov, A. Tropsha, Phantom PAINS: Problems with the utility of alerts for pan-
assay interference compounds, Journal of Chemical Information and Modeling, 57 (2017) 417-427. 
[59] F. Wang, P. Zhao, C. Xi, Copper-catalyzed one-pot synthesis of 2-thioxo-2,3-dihydroquinazolin-4(1H)-
ones from ortho-bromobenzamides and isothiocyanates, Tetrahedron Letters, 52 (2011) 231–235. 
[60] M. Kuanar, B.K. Mishra, Applicability of Williams-Norrington model for quantitative structure spectra 
relationship, Indian Journal of Chemistry, Section A: Inorganic, Bio-inorganic, Physical, Theoretical & 
Analytical Chemistry, 34 (1995) 721-723. 
[61] N. Seyyedi, F. Shirini, M.S. Nikoo Langarudi, DABCO-based ionic liquids: green and recyclable 
catalysts for the synthesis of barbituric and thiobarbituric acid derivatives in aqueous media, RSC Advances, 6 
(2016) 44630-44640. 
[62] M.K. Haldar, M.D. Scott, N. Sule, D.K. Srivastava, S. Mallik, Synthesis of barbiturate-based methionine 
aminopeptidase-1 inhibitors, Bioorganic & Medicinal Chemistry Letters, 18 (2008) 2373-2376. 
[63] J.A. Vida, C.M. Samour, M.H. O'Dea, T.S.T. Wang, W.R. Wilber, J.F. Reinhard, Analgesics. 1. Selected 
5-substituted 5-propionoxybarbituric acids, Journal of Medicinal Chemistry, 17 (1974) 732-736. 
[64] H.C. Scarborough, Pyrano[2,3-d]- and pyrido[2,3-d]pyrimidines, The Journal of Organic Chemistry, 29 
(1964) 219-221. 
[65] H. Biltz, H. Wittek, Über alkylierte und acylierte barbitursäuren, Berichte der Deutschen Chemischen 
Gesellschaft (A and B Series), 54 (1921) 1035-1058. 
[66] P. Singh, J. Kaur, A. Bhardwaj, Synthesis of highly functionalized barbituric acids and study of their 
interactions with p-glycoprotein and Mg2+-potential candidates for multi drug resistance modulation, 
European Journal of Medicinal Chemistry, 45 (2010) 1256-1262. 
[67] V.K. Ahluwalia, V.K. Garg, A. Dahiya, M.D. Alauddin, A convenient synthesis of 6-ethoxycarbonyl-4-
oxo-1,2,3,4-tetrahydro-7H-pyrano(2,3-d)pyrimidin-7-ones, Indian Journal of Chemistry, Section B: Organic 
Chemistry Including Medicinal Chemistry, 34 (1995) 51-53. 
[68] S. Gupta, L.M. Rodrigues, A.P. Esteves, A.M. Oliveira-Campos, M.S. Nascimento, N. Nazareth, H. 
Cidade, M.P. Neves, E. Fernandes, M. Pinto, N.M. Cerqueira, N. Bras, Synthesis of N-aryl-5-amino-4-








Figure 1. Enamine A and imine B tautomeric forms. 
Figure 2. In vitro XO inhibitory activity of compounds 2c, 2d, 6c-f and allopurinol. Results are expressed as average 
values ± standard error of the mean (SEM). A p < 0.05 versus negative control in the statistical significance analysis 
(Student´s t-test) was observed for all compounds except for 6d. 
Figure 3. In vitro DPPH radical scavenging activity for 5-hydrazinylethylidenepyrimidines 6a-g, 1-(pyrimidin-5-
ylidene)ureas 8d, 8f and Trolox (positive control). Results are expressed as average values ± SEM. A p < 0.05 versus 
negative control in the statistical significance analysis (Student´s t-test) was observed for all compounds. 
Figure 4. In vitro cytotoxic effect of compounds 6c, 6d, 7a-j and 5-fluorouracil (5-FU) in normal human dermal 
fibroblasts (NHDF) and in mammalian breast cancer cells (MCF-7). Results are expressed as average values ± SEM. 




Table 1. In vitro IC50 values for XO inhibition and DPPH radical scavenging activity of compounds 2c, 2d, 6c-e and 
respective references allopurinol and Trolox. 
 
Scheme Captions 




















Compound XO (µM)a 
 DPPH (µM) a 
20 min 60 min 
2c 26.1 nd b nd b 
2d 31.5 nd b nd b 
6c 24.3 22.6 18.8 
6d nd b 23.9 20.4 
6e 27.9 23.9 23.8 
Allopurinol 3.2 nd b nd b 
Trolox nd b 33.8 35.9 
a IC50 values represent as mean of three determinations. 
b nd: not determined 
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